

1 From multiplicity of infection to 2 force of infection for sparsely 3 sampled *Plasmodium falciparum* 4 populations at high transmission

5 Qi Zhan^{1*}, Kathryn E. Tiedje², Karen P. Day², Mercedes Pascual^{3,4,5*}

***For correspondence:**

qizhan@uchicago.edu (QZ);
mp6774@nyu.edu (MP)

Present address: ⁵Department,
Institute, Country; [¶]Department,
Institute, Country

6 ¹Committee on Genetics, Genomics and Systems Biology, The University of Chicago,
7 Chicago, IL, USA; ²Department of Microbiology and Immunology, Bio21 Institute and
8 Peter Doherty Institute, The University of Melbourne, Melbourne, Australia;
9 ³Department of Biology, New York University, New York, NY, USA; ⁴Department of
10 Environmental Studies, New York University, New York, NY, USA; ⁵Santa Fe Institute,
11 Santa Fe, NM, USA

13 **Abstract** High multiplicity of infection or MOI, the number of genetically distinct parasite strains
14 co-infecting a single human host, characterizes infectious diseases including falciparum malaria
15 at high transmission. It accompanies high asymptomatic *Plasmodium falciparum* prevalence
16 despite high exposure, creating a large transmission reservoir challenging intervention. High MOI
17 and asymptomatic prevalence are enabled by immune evasion of the parasite achieved via vast
18 antigenic diversity. Force of infection or FOI, the number of new infections acquired by an
19 individual host over a given time interval, is the dynamic sister quantity of MOI, and a key
20 epidemiological parameter for monitoring the impact of antimalarial interventions and assessing
21 vaccine or drug efficacy in clinical trials. FOI remains difficult, expensive, and labor-intensive to
22 accurately measure, especially in high-transmission regions, whether directly via cohort studies
23 or indirectly via the fitting of epidemiological models to repeated cross-sectional surveys. We
24 propose here the application of queuing theory to obtain FOI on the basis of MOI, in the form of
25 either a two-moment approximation method or Little's law. We illustrate these methods with
26 MOI estimates obtained under sparse sampling schemes with the recently proposed "varcoding"
27 method, based on sequences of the *var* multigene family encoding for the major variant surface
28 antigen of the blood stage of malaria infection. The methods are evaluated with simulation
29 output from a stochastic agent-based model, and are applied to an interrupted time-series study
30 from Bongo District in northern Ghana before and immediately after a three-round transient
31 indoor residual spraying (IRS) intervention. We incorporate into the sampling of the simulation
32 output, limitations representative of those encountered in the collection of field data, including
33 under-sampling of *var* genes, missing data, and usage of antimalarial drug treatment. We address
34 these limitations in MOI estimates with a Bayesian framework and an imputation bootstrap
35 approach. We demonstrate that both proposed methods give good and consistent FOI estimates
36 across various simulated scenarios. Their application to the field surveys shows a pronounced
37 reduction in annual FOI during intervention, of more than 70%. The proposed approach should
38 be applicable to the many geographical locations where cohort or cross-sectional studies with
39 regular and frequent sampling are lacking but single-time-point surveys under sparse sampling
40 schemes are available, and for MOI estimates obtained in different ways. They should also be
41 relevant to other pathogens of humans, wildlife and livestock whose immune evasion strategies

42 are based on large antigenic variation resulting in high multiplicity of infection.

43

44 Introduction

45 Despite substantial control and elimination efforts, falciparum malaria in high-transmission re-
46 gions continues to be a major public health concern, as a cause of mortality among young chil-
47 dren and considerable economic burden in many countries especially in sub-Saharan Africa (*World*
48 *Health Organization, 2023*). It thus remains important to robustly evaluate the effects of inter-
49 vention efforts in these regions, including on transmission intensity. Collectively, epidemiological
50 studies have revealed a multiplicity of metrics that are associated with parasite transmission (*Tust-*
51 *ing et al., 2014*). Chief among them is the force of infection (FOI), defined as the number of new
52 *Plasmodium falciparum* infections acquired by an individual host over a given time interval. FOI
53 has been found to reflect risk of infection and to be tightly associated with risk of clinical episodes
54 (*Mueller et al., 2012*). While other metrics may describe the relationship between transmission
55 intensity and the burden of malaria illness on global or continental scales (*Carneiro et al., 2010*;
56 *Beier et al., 1994*), FOI can relate local variation in malaria burden to transmission (*Mueller et al.,*
57 *2012*). Despite being recognized as a key epidemiological parameter for malaria surveillance, FOI
58 remains difficult, expensive, and labor-intensive to accurately measure, either directly or indirectly
59 via the fitting of epidemiological models. As molecular tools for parasite genomics become more
60 readily available, they are contributing to new approaches. In particular, molecular advances are
61 providing a basis for estimating a sister “static” quantity, the multiplicity of infection (MOI), defined
62 as the number of genetically distinct parasite strains co-infecting a single human host (*Zhong et al.,*
63 *2018; Chang et al., 2017; Ruybal-Pesántez et al., 2022; Tiedje et al., 2022; Labbé et al., 2023*). We
64 can therefore ask whether we can go further and on the basis of MOI obtain the dynamical, rate,
65 quantity of force of infection?

66 Prior efforts to directly measure FOI included clearing infections and observing time to re-
67 infection. Infant conversion rate, the time to a patent infection in uninfected children less than
68 1-year of age, was widely used in the 1950s to 1970s (*Macdonald, 1950; Pull and Grab, 1974*). An
69 alternative way was to perform detection of parasites by light microscopy for subjects following anti-
70 malarial treatment (*Msuya and Curtis, 1991; Alonso et al., 2004*). In both cases, FOI was measured
71 directly in either a naturally uninfected cohort (e.g. infants or uninfected immigrants) or by artifi-
72 cially creating a cohort of uninfected individuals through treatment with antimalarial drugs, which
73 was then followed to estimate the attack rate or proportion acquiring infection over some time
74 period. More recently, with the advent of molecular approaches to malaria epidemiology, direct
75 and more precise measures of FOI can be generated by genotyping individual parasite infections
76 (*Mueller et al., 2012; Hofmann et al., 2017*). Individual clones can be tagged by a set of molecular
77 markers which are polymorphic, a precondition for longitudinally tracking and differentiating indi-
78 vidual parasite clones. PCR-based techniques also offer the added advantage of higher sensitivity
79 by early infection detection, when parasite density is under the detection limit of microscopy (*John-*
80 *ston et al., 2006*). It remains challenging however to accurately differentiate a truly new infection
81 from the temporary absence from the peripheral blood of an old infection and its subsequent re-
82 emergence (*Daubersies et al., 1996*). This is primarily because some of these popular polymorphic
83 molecular markers have a relatively low resolution for differentiating different strains from one
84 another. Despite increased access to better techniques, the determination of molecular FOI re-
85 mains challenging, labor-intensive, and costly, as it still involves closely monitoring and genotyping
86 a large cohort over some period of time.

87 Alternatives to direct measurements involve cross-sectional surveys with FOI estimated by fit-
88 ting simple epidemiological models, including Markov models corresponding to the reverse cat-
89 alytic formulations parameterized from changes in prevalence with age (*Bekessy et al., 1976; Muench,*
90 *1959; Smith and Vounatsou, 2003*), or immigration-death models informed by the values of MOI

91 across age groups (*Felger et al., 2012*), or iterations between a generalized linear mixed model and
92 a mathematical Susceptible-Infected-Susceptible model (*Mugenyi et al., 2017*). These model-fitting
93 procedures require empirical data sampled regularly and frequently, such as age-stratified cohorts
94 with a large number of individuals sampled six times a year, to account for the high heterogeneity
95 and variation in FOI and infection duration (*Laishram et al., 2012; Simpson et al., 2002; Langhorne*
96 *et al., 2008; Childs and Buckee, 2014; Chang et al., 2016; Ashley and White, 2014*), both of which
97 are dependent on the interplay between hosts immunity profiles and antigen composition of any
98 infection (*Piper et al., 1999; Molineaux et al., 2002; Doolan et al., 2009; Barry et al., 2007*). In addi-
99 tion, they may suffer from identifiability problems with more than one value of given parameters
100 of interest resulting in similar likelihood or other model selection metrics (*Mugenyi et al., 2017*).
101 Hence, these indirect measurements share limitations with direct ones.

102 As a result of the above-described challenges, FOI has not become a readily available epidemio-
103 logical quantity across time and geographical locations. In contrast, various approaches have been
104 proposed to estimate MOI from clinical samples, involving size-polymorphic antigenic markers, mi-
105 crosatellites, and panels of biallelic single nucleotide polymorphisms (SNPs) (*Felger et al., 1994;*
106 *Konaté et al., 1999; Anderson et al., 2000b; Daniels et al., 2008; Chang et al., 2017*). Because Plas-
107 modium parasites reproduce asexually during haploid stages within human hosts (*Guttery et al.,*
108 *2012*), signatures of polymorphic genotypes are evidence of multiclonal infection. As methods for
109 disentangling the molecular complexity of natural parasite infections across various transmission
110 settings emerge and mature, MOI becomes much more commonly and easily surveyed across
111 space and time. Although this quantity remains one of the most frequently used genetic metrics
112 of parasite transmission (*Arnot, 1998; Sondo et al., 2020*), it is by definition a number and not a
113 rate.

114 A natural correlation exists however between MOI and FOI mediated by the duration of infec-
115 tion, which provides an opportunity to convert the former into the latter. This conversion has been
116 particularly challenging because disease transmission and dynamics display heterogeneity in time
117 and across individuals (*Laishram et al., 2012; Simpson et al., 2002; Langhorne et al., 2008*), duration
118 of infection information is highly heterogeneous across a multiplicity of factors and mostly lacking
119 (*Childs and Buckee, 2014; Chang et al., 2016; Ashley and White, 2014; Bretscher et al., 2011*), and
120 the majority of MOI estimates are obtained under sparse sampling schemes. Rather than cohort-
121 studies or cross-sectional studies with regular and frequent sampling, most often single-time-point
122 surveys are implemented, typically in wet (high-transmission) and dry (low-transmission) seasons
123 (*Tiedje et al., 2022; Abukari et al., 2019*). Although MOI estimates from those single-time-point
124 cross-sectional surveys have been used to address a number of questions such as whether multi-
125 ple infections protect against clinical attacks, and whether each additional infecting clone is asso-
126 ciated with a higher prospective risk or a higher odd of treatment failure (*Earland et al., 2019; Lee*
127 *et al., 2006*), the sparse sampling scheme has limited their translation into a transmission rate.

128 In this work, we propose to specifically use these MOI estimates for the purpose of FOI inference.
129 We present two mathematical modeling frameworks based on queuing theory for this purpose
130 (*Choi et al., 2005; Little and Graves, 2008*), and illustrate their application with empirical molecular
131 data collected in the Bongo District of northern Ghana (*Tiedje et al., 2022, 2023*). The proposed
132 methods can be easily scaled up and applied across different geographical locations and time.
133 They are potentially applicable to the many geographical locations where cohort or cross-sectional
134 studies with regular and frequent sampling are lacking but single-time-point surveys are available.
135 We evaluate their performance with numerical simulation of an extended stochastic agent-based
136 model (ABM) (*He et al., 2018*) for both a closed system and an open one under two different spatial
137 scenarios, specifically two populations coupled via migration and a local population with migration
138 from a regional pool, with either constant or seasonal transmission. We further consider cases of
139 heterogeneous transmission in which a high-risk group of hosts receives the majority of infectious
140 bites. We also examine scenarios in which the times of local transmission events follow differ-
141 ent statistical distributions. We incorporate limitations representative of those encountered in the

142 collection of field data into the sampling of simulation output, including under-sampling of *var*
143 genes, missing data, and usage of antimalarial drug treatment. We obtain MOI estimates with a
144 Bayesian framework and a bootstrap imputation approach correcting for all the aforementioned
145 errors. The Bayesian method accounts for the under-sampling of *var* genes for individual isolates.
146 The bootstrap imputation approach accounts for the missing data error and the usage of anti-
147 malarial treatment by removing the samples for individuals who are under the impact of the two
148 and then inferring their MOI estimates by sampling from those of the remaining population. We
149 show that our Bayesian method and bootstrap imputation approach are robust to considerable
150 fractions of individuals with their MOI information missing or under antimalarial treatment, com-
151 parable to those from our field surveys in northern Ghana. We demonstrate further that based
152 on MOI estimates obtained in this way, both proposed methods give good and consistent FOI es-
153 timates across various simulated scenarios. After validating their performance with simulation
154 output, we illustrate the application of the proposed methods to empirical data collected from an
155 interrupted time-series study from Bongo District in northern Ghana that involved a three-round
156 transient indoor residual spraying (IRS) intervention (*Tiedje et al., 2022, 2023*). We conclude with
157 discussion of the relationship between FOI and another commonly used surrogate variable for
158 transmission intensity, the entomological inoculation rate or EIR, defined as the number of infec-
159 tious bites received by an individual over a given time period (*Shaukat et al., 2010*). We discuss how
160 this relationship explains the known difficulty in relating transmission to malaria burden at more
161 refined local scales, and that of achieving sustainable and considerable transmission reductions in
162 high-transmission endemic regions. We further discuss how this relationship might be informative
163 of malaria immunity, and within-host competitive interactions of co-infecting strains.

164 Results

165 **The MOI estimates at the population level for surveys in Ghana resemble those** 166 **under high-intensity and heterogeneous transmission from numerical simulation**

167 While any polymorphic marker should be suitable in theory for estimating MOI, the common high
168 number of multiclonal infections in high-transmission endemic regions limits the ability to accu-
169 rately do so in practice (*Tiedje et al., 2022; Ruybal-Pesántez et al., 2017; Touray et al., 2020; Labbé*
170 *et al., 2023*). A multigene family known as *var* which encodes for hyper-diverse antigenic variation
171 in the parasite provides one proposed solution, described in the Materials and Methods and re-
172 ferred to as "varcoding" (*Ruybal-Pesántez et al., 2022; Tiedje et al., 2022*). We recently extended the
173 method to a Bayesian formulation to account for the measurement error from under-sampling or
174 imperfect detection of *var* genes in the collection of empirical data (*Tiedje et al., 2023*), with details
175 summarized in the Materials and Methods-Bayesian approach to MOI estimation with "varcoding".
176 Additionally, empirical surveys suffer from a missing data error due to factors including the detec-
177 tion limit of the selected method and low DNA quality, and they contain a fraction of individuals
178 under antimalarial drug treatment during a previous window of time. Antimalarial treatment ei-
179 ther prevents new infections or clears existing ones by shortening their duration, which potentially
180 violates the assumptions of our two proposed methods for FOI inference. This is because the
181 two methods rely on a known and fixed distribution of duration of infection for 1-5 year-old chil-
182 dren. Because these children's immune profile is similar to that of naive hosts, for this specific
183 sub-population class, the duration of infection can be approximated by that of malaria therapy
184 patients with neurosyphilis and no history of prior exposure to malaria (*Collins and Jeffery, 1999;*
185 *Maire et al., 2006*). Details can be found in Materials and Methods-Infering FOI from MOI esti-
186 mates. We address both types of errors with a bootstrap imputation approach whose details are
187 included in Materials and Methods-The under-sampling of infections in estimates of MOI from em-
188 pirical surveys, and Materials and Methods-Antimalarial drug treatment of infections in estimates
189 of MOI from empirical surveys.

190 Because we rely on MOI estimates to derive FOI ones, we first conduct here an investigation of

191 the MOI estimates obtained under the impact of each of these aforementioned errors, and of all
192 combined, in comparison with true MOI values. We rely on the simulated output from our agent-
193 based model (ABM) of malaria transmission for which true MOI values are known. The ABM is de-
194 scribed in detail in previous studies of *P. falciparum*'s population structure based on *var* genes (*He*
195 *et al., 2018*). We provide additional details on its formulation, including extensions implemented
196 to the model for this work, and on the experimental design of simulation output in Appendix 1-
197 Simulation data. See also Appendix 1-Figure 5A-C for illustrations of the experimental design.

198 Our analysis shows that MOI estimates obtained with the Bayesian method and the bootstrap
199 imputation approach with all the aforementioned errors present, are close to the true MOI val-
200 ues. We measure the difference between estimated and true MOI by the difference in their mean
201 value and the Kolmogorov-Smirnov statistic, which quantifies the distance in their cumulative distri-
202 bution function. Results are included in the supplementary file 1-MOImethodsPerformance.xlsx,
203 and illustrated in Appendix 1-Figure 6. The bootstrap imputation approach corrects well for the
204 missing data error and the antimalarial drug treatment issue. The Bayesian method reduces the
205 under-sampling of *var* genes error, resulting in a noticeable improvement relative to the origi-
206 nal *var* coding method which relies on a constant repertoire size to convert the number of de-
207 tected non-upsA DBL α types to the estimated MOI value, and hence does not consider the vari-
208 ation in repertoire size introduced by the under-sampling of *var* genes. See supplementary file
209 2-BayesianImprovement.xlsx, Appendix 1-Figure 7, and Appendix 1-A comparison between the
210 Bayesian method and the original *var* coding one for further details.

211 The MOI estimates at the population level for simulation output under high-intensity and het-
212 erogeneous transmission are similar in range to the ones for surveys in Ghana (Appendix 1-Figure
213 6 and 8-9). The respective distributions of MOI estimates across the different surveys in Ghana
214 and from the simulated outputs are not Poisson-distributed (Appendix 1-Test of deviation from
215 Poisson homogeneity in MOI estimates, supplementary file 3-deviationFromPoissonTest.xlsx) (*Pot-*
216 *thoff and Whittinghill, 1966; Lloyd-Smith et al., 2005*). The deviation of empirical MOI estimates
217 from a Poisson distribution indicates that either the arrival of inoculations deviates from a homo-
218 geneous Poisson process, or some latent heterogeneity causes inoculation duration distribution
219 to be over-dispersed. Despite these conditions which challenge the conversion of MOI estimates
220 to their corresponding FOI values, the proposed methods below are still applicable (see Materials
221 and Methods-Inferring FOI from MOI estimates for details).

222 **The Two-Moment Approximation and Little's Law approaches give good and con-** 223 **sistent estimates for FOI across different simulated scenarios**

224 We start with the result of the homogeneous exposure risk scenario for seasonal transmission and
225 a closed system based on the two-moment approximation approach and Little's law. The times of
226 local transmission events follow a Gamma distribution (Appendix 1-Figure 5C). Across pre-IRS, low-
227 , mid-, and high-coverage IRS, the 95% confidence intervals of annual FOI per host and the full
228 sampling distribution from bootstrap analysis are narrow and concentrated, containing, or very
229 close to, the true FOI values (Figure 1). We infer FOI estimates based respectively on the true MOI
230 values, on the MOI estimates with the Bayesian method and a bootstrap imputation approach
231 correcting for all aforementioned errors, and on the MOI estimates with one source of error at
232 a time corrected by either the Bayesian method or the bootstrap imputation approach, namely
233 under the missing data error, the under-sampling of *var* genes, and the antimalarial treatment
234 issue. The FOI estimates obtained with the two methods based on the true MOI values differ only
235 slightly from the true FOI values. The FOI estimates based on the MOI estimates with the Bayesian
236 method and a bootstrap imputation approach correcting for all errors exhibit a somewhat larger,
237 but still small, difference from the true FOI values.

238 We continue with the result of the heterogeneous exposure risk scenarios in which a high-risk
239 group ($\frac{2}{3}$ of the total population) receives around 94% of all bites whereas a low-risk group ($\frac{1}{3}$ of
240 the total population) receives the remaining bites (Appendix 1-Figure 5C). Transmission is seasonal




Figure 1. Confidence intervals for estimated mean FOI values in simulated risk scenarios with homogeneous exposure, before and during IRS interventions with three different coverage levels. The times of the local transmission events follow a Gamma distribution, and transmission is seasonal with the spatial setting corresponding to a closed system. We provide FOI estimates based respectively on the true MOI values, on the MOI estimates with the Bayesian method and a bootstrap imputation approach correcting for all aforementioned errors, and on the MOI estimates with one source of error at a time corrected by either the Bayesian method or the bootstrap imputation approach, namely under the missing data error, the under-sampling of *var* genes, and the antimalarial treatment issue. To obtain the true mean FOI per host per year, we divide the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.

241 and the spatial setting corresponds to a semi-open system (Appendix 1-Figure 5A-B, and Appendix
 242 1-Simulation data). The times of local transmission events are Gamma-distributed (Appendix 1-
 243 Figure 5C). Across pre-IRS, low-, mid-, and high-coverage IRS, the 95% confidence intervals and the
 244 full sampling distribution from bootstrap analysis are narrow and concentrated, containing, or very
 245 close to, the true FOI values (Figure 2).

246 The performance of the two methods across other simulated scenarios is demonstrated in
 247 Appendix 1-Figure 10-14. Details for deriving the confidence intervals are provided in Appendix
 248 1-Confidence intervals for mean and variance.

249 **The Two-Moment Approximation and Little's Law approaches give consistent FOI**
 250 **estimates for empirical surveys from Bongo District in northern Ghana**

251 The two-moment approximation approach and Little's law also give consistent estimates of the
 252 FOI using the empirical MOI estimates from surveys in Ghana. We provide in Materials and Meth-
 253 ods, further details and proposed solutions regarding the under-sampling of *var* genes, as well
 254 as antimalarial drug treatment and missing data due to factors such as the low detection limit of
 255 the selected method and low DNA quality, in obtaining empirical MOI estimates. Since PCR has
 256 a high, but yet not perfect power of infection detection, we further assume three levels of sen-
 257 sitivity, ranging from 0% of PCR-negative individuals carrying infection or a detection of 100% of
 258 the infected individuals (high detectability), to 5% of PCR-negative individuals carrying infections




Figure 2. Confidence intervals for the estimated mean FOI values in simulated risk scenarios with heterogeneous exposure, before and during IRS interventions with three different coverage levels.

The times of the local transmission events follow a Gamma distribution, and the transmission is seasonal with the spatial setting corresponding to a semi-open system. We provide FOI estimates based respectively on the true MOI values, on the MOI estimates with the Bayesian method and a bootstrap imputation approach correcting for all aforementioned errors, and on the MOI estimates with one source of error at a time corrected by either the Bayesian method or the bootstrap imputation approach, namely under the missing data error, the under-sampling of *var* genes only, and the antimalarial treatment issue. To obtain the true mean FOI per host per year, we divide the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.

259 (mid detectability), to 10% of PCR-negative individuals carrying infections (low detectability). The
260 impact of antimalarial treatment on infection status and duration, and therefore on MOI values,
261 is difficult if not impossible to disentangle due to the complex biology of the parasite. We thus
262 consider the following two extremes which should bound reality. Antimalarial treatment either
263 does not impact treated individuals' infection status and MOI values, or it does affect both. For the
264 former assumption (hereafter assumption 1), we include the infection status and MOI estimates of
265 these treated individuals when inferring FOI. For the latter assumption (hereafter assumption 2),
266 we discard their infection status and MOI estimates and sample instead their MOI values from the
267 microscopy-positive individuals who were not under the missing data error or antimalarial treat-
268 ment.

269 We start with the two-moment approximation approach. The estimated values of the annual
270 mean FOI before IRS (Appendix 1-Figure 5E, the pre-IRS phase) are based on Survey 1 (S1; Oct
271 2012) and Survey 2 (S2; May/Jun 2013), undertaken at the end of the wet/high-transmission and
272 dry/low-transmission seasons, respectively. Under assumption 1, the FOI estimates are respec-
273 tively 5, 5.214286, and 5.367647, assuming respectively that 0%, 5%, 10% PCR-negative individuals
274 carry infections. Under assumption 2, they are equal to 5.983607, 6.186441, and 6.293103, assum-
275 ing respectively that 0%, 5%, 10% PCR-negative individuals carry infections. The estimated values
276 for the year when IRS was discontinued (Appendix 1-Figure 5E, the post-IRS phase right after IRS
277 was interrupted) are based on Survey 3 (S3; Oct 2015) and Survey 4 (S4; May/Jun 2016), under-
278 taken at the end of the wet/high-transmission and dry/low-transmission seasons, respectively. The
279 corresponding FOI estimates under assumption 1 are 0.7635983, 0.9864865, 1.140625, assuming
280 respectively that 0%, 5%, 10% PCR-negative individuals carry infections. The corresponding FOI es-
281 timates under assumption 2 are 1.46, 1.615044, 1.738095, assuming respectively that 0%, 5%,
282 10% PCR-negative individuals carry infections.

283 We then consider Little's law. The estimated annual mean FOI values before IRS under as-
284 sumption 1 are 4.83786, 5.089157, 5.237725, for 0%, 5%, 10% PCR-negative individuals carrying
285 infections respectively. For comparison, the estimated annual mean FOI values before IRS under
286 assumption 2 are 5.92716, 6.099559, 6.224758. The corresponding estimated values immediately
287 post-IRS under assumption 1 are 0.764853, 0.9870203, 1.14117. Those values under assumption
288 2 are 1.456373, 1.622026, 1.741665.

289 The two-moment approximation and Little's law approaches give consistent FOI estimates for
290 empirical surveys from Bongo District in northern Ghana. There is a considerable reduction in
291 FOI, of more than 80% or 70% under the two assumptions respectively, which indicates that the
292 three-round IRS intervention although transient was efficient and strong. Reality is likely to lie
293 somewhere in between the two bounding assumptions on the impact of antimalarial treatment
294 on infection status and MOI values, so that such treatment may have a non-negligible effect on
295 some individuals but not others. Regardless, the actual estimates of FOI are similar in magnitude
296 and the trend in the change of FOI across intervention, and so the evaluation of the impact of such
297 intervention, remain qualitatively the same.

298 The 95% confidence intervals and the full sampling distribution from bootstrap analysis are
299 narrow and concentrated (Figure 3).

300 **The inferred FOI and the directly measured EIR for surveys in Ghana are consistent** 301 **with the relationship between the two measures from previous studies**

302 We plot the measured mean annual EIR against the estimated mean annual FOI, and the trans-
303 mission efficiency (the ratio between FOI and EIR) against the measured mean annual EIR from
304 previous field studies, summarized in (*Smith et al., 2010*) (Figure 4). The estimation of FOI in these
305 studies was primarily based on fitting a simple epidemiological model to age-stratified prevalence
306 from cross-sectional parasitological studies (*Smith et al., 2010; Pull and Grab, 1974*); that of EIR
307 was based on diverse methods including exit bait collection, human bait collection, pyrethrum
308 spray collection, night bite collection, and outdoor resting collection (*Smith et al., 2010*). The red




Figure 3. Confidence intervals for the estimated mean FOI values in Ghana surveys across a transient three-round IRS intervention based on the combination of surveys from the wet/high-transmission and dry/low-transmission seasons (A) The estimated FOI values when considering that antimalarial treatment does not affect infection status and MOI values in treated individuals (assumption 1). (B) The estimated FOI values when considering instead that antimalarial treatment affects infection status and MOI values in treated individuals (assumption 2). High, mid, and low detectability correspond to 0%, 5%, and 10% of PCR-negative individuals carrying infections respectively. Minimum, 5% quantile, median, 95% quantile, and maximum are shown in the boxplot.

309 line corresponds to the functional curve fitted to these data points as described in Materials and
 310 Methods-Conversion between FOI and EIR, as initially proposed in (*Smith et al., 2010*).

311 Based on these data pairs, we see that the values for mean annual FOI are well below an em-
 312 pirical limit of 20. Due to the highly non-linear pattern between FOI and EIR, there is no single
 313 constant factor that converts FOI to EIR (or the opposite) across different empirical settings. The
 314 transmission efficiency in high-intensity endemic regions is extremely low, with an average annual
 315 EIR reaching values of a few hundred to a thousand, whereas the average annual FOI takes values
 316 of only about 5-10. In future applications, when applying our proposed methods to obtain FOI es-
 317 timates from MOI under sparse sampling schemes from specific geographical regions, we can rely
 318 on this functional curve to convert the FOI estimates to corresponding EIR values. There is how-
 319 ever an inherently high variance associated with the conversion. Nevertheless, overall, our paired
 320 EIR (directly measured by the entomological team in Ghana (*Tiedje et al., 2022*)) and FOI values
 321 are reasonably consistent with the data points from previous studies, suggesting the robustness
 322 of our proposed methods.

323 **The variance inferred reflects transmission intensity and heterogeneity across in-** 324 **dividuals**

325 We have focused so far on estimation of the mean for FOI in both the simulation output and the em-
 326 pirical data. The two-moment approximation method further gives an estimate for the variance of
 327 the inter-arrival times of infections. We examine the variance inferred across all simulated scenar-
 328 ios. We find that regardless of the magnitude of the variance for FOI or the degree of heterogeneity
 329 in exposure risks across individual human hosts, the estimated mean FOI at the individual level by
 330 the two proposed methods, when aggregated across all individuals within the local population,
 331 reflects the total number of infections accumulated by that population.

332 Overall, seasonal runs have slightly larger variance than non-seasonal runs (Appendix 1-Figure
 333 15). Runs with a heterogeneous transmission, in which a high-risk group of individuals receives




Figure 4. Saturation in FOI with EIR and the non-linear relationship between these two quantities from previous field studies. (A) and (B) includes our empirical estimates under the assumption that antimalarial treatment does not affect infection status and MOI values in treated individuals. (C) and (D) includes our estimates under the assumption that the treatment affects such quantities. The points correspond to paired EIR-FOI values from the literature, summarized in (Smith et al., 2010), and the crosses indicate the range of those values when several estimates of the EIR or the FOI were reported or estimated for the same location. Namely, a line or a cross was plotted with its center at the arithmetic mean and with legs that connect the center to each one of the estimates, and similarly for the scenario when ranges were reported for both variables. The red function curve is the best-fit to these paired EIR-FOI values from (Smith et al., 2010). The black hollow diamond and circle correspond to the Ghana data, for our respective estimates of FOI with the two methods and the EIR measure in the field by the entomological team (Tiedje et al., 2022).

334 more than 90% of the total bites, have slightly higher variance than those with a homogeneous
335 transmission in which bites do not exhibit such variation. These findings are consistent with expect-
336 tations since seasonality and heterogeneity in transmission should increase the dispersion of FOI
337 across individuals, and consequently of MOI. The inferred variance correlates most significantly
338 with the inferred mean. In particular, when the mean FOI is close to 0, the variance is large. This is
339 intuitive as significant deviation from the close-to-zero mean FOI (or, large inter-arrival times, for
340 example, at the order of several years) would be required to generate some fraction of individual
341 hosts with MOI greater than zero.

342 Discussion

343 Building on estimates of the multiplicity of infection under sparse sampling schemes, we have
344 demonstrated the feasibility of converting this quantity to estimates of the force of infection. Across
345 a wide range of numerical simulation scenarios with the extended stochastic agent-based model,
346 the two-moment approximation approach and Little's law are shown to provide consistent and
347 good FOI estimates, and to do so based on the MOI estimates obtained with the Bayesian method
348 and bootstrap imputation approach in the presence of various types of errors commonly encoun-
349 tered in the collection of empirical data. The Bayesian method addresses in particular the under-
350 sampling of *var* genes and helps alleviate the underestimation of MOI estimates.

351 In high-transmission endemic regions which continue to pose major challenges to malaria elim-
352 ination, clinical infections typically constitute a small fraction of the overall reservoir of infection
353 behind the force of infection, of approximately 2% at the end of wet season and less than 1% at the
354 end of dry one (*Tiedje et al., 2022*). Individuals can seek however antimalarial drug treatment in
355 response to symptoms or the perception of transmission risk, which affects duration of infection
356 and would interfere with our FOI estimates. Rather than attempting a correction of the duration
357 of infection (which given the complexity of the biology involved would be difficult if not impossi-
358 ble at this stage), we implement instead the removal of the samples for treated individuals, and
359 impute their MOI estimates with a bootstrap approach based on the remaining population. The
360 proposed bootstrap imputation approach is robust to considerable fractions of individuals treated
361 or missing MOI information, comparable to values from our field surveys in Ghana.

362 The application of both methods typically requires an evolving time series as it is observed over
363 a long period of time. Because we do not have time series observation of MOI estimates for any
364 specific individual host, we treat different individual hosts sampled at the same time point as if
365 each one represented an observation of the process at a single time point and ignore any individ-
366 ual heterogeneity in their biology. This approximation turns out to be a sensible one and the bias
367 due to interval edge effects when the system does not begin and end empty turns out to be small
368 because the FOI estimates obtained with the two methods based on the true MOI values differ by
369 only a very small amount from the true FOI values in the simulation output. Despite seasonality
370 and heterogeneity in exposure risk, MOI estimates obtained under sparse sampling schemes are
371 sufficient to recover the mean annual FOI. The inferred mean annual FOI when aggregated across
372 all individuals faithfully reflects the total number of new *P. falciparum* infections acquired by the en-
373 tire population. The inferred variance indicates transmission intensity and the degree of deviation
374 from a homogeneous Poisson process, for the arrival of infections at the individual level. Thus, the
375 flexibility and generality of these two proposed methods allow robust estimation of an important
376 metric for malaria transmission across geographical locations and time, where single-time-point
377 surveys are implemented, typically in wet (high-transmission) and dry (low-transmission) seasons,
378 and information about FOI was previously unobtainable.

379 We illustrate the application of these two methods with molecular data from Bongo District in
380 northern Ghana, a high-transmission endemic region for which estimation of multiplicity of infec-
381 tion and related FOI has been challenging. The three-round transient IRS intervention was strong
382 and effective, resulting in a significant, more than 70% reduction in FOI.

383 Beyond describing basic malaria epidemiology and measuring outcomes of intervention, the
384 FOI estimates obtained with these two proposed methods can inform process-based models for
385 the population dynamics of complex infectious diseases. They can serve as values for priors when
386 seeking to parameterize and validate more complex agent-based or equation-based models, in a
387 way that reduces computational cost, improves efficiency, and reduce the degree of freedom or
388 identifiability issues.

389 Although we have focused on infections caused by *P. falciparum*, our approach should be appli-
390 cable to other *Plasmodium* parasites responsible for malaria transmission, including *P. vivax*, with
391 distinctive life cycles. For *P. falciparum*, FOI is closely linked to the number of newly acquired infec-
392 tions from infectious mosquito bites, whereas for *P. vivax*, clones appearing in the blood-stream
393 can either originate directly from recent infective mosquito bites or relapsing liver hypnozoites
394 (Chu and White, 2016). Regardless of infection source, MOI estimates and related FOI ones should
395 represent the number of effective infections which reach the blood stage.

396 As expected from estimating FOI based on MOI values, the estimation accuracy of the latter is
397 crucial for that of the former. In high-transmission endemic regions, repertoires of *var* genes in
398 co-infecting genomes can still be partially overlapping in their composition. This low overlap re-
399 sults in a reduced number of different *var* genes being sequenced and identified, which can lead
400 to an underestimation of MOI. In addition, recent studies have identified a signature of parasite
401 co-transmission from a single mosquito bite even in high-transmission endemic regions (Nkhoma
402 et al., 2020; Wong et al., 2017). This conclusion was based primarily on clinical or symptomatic
403 infections whereas asymptomatic prevalence is high and constitutes the majority of transmission
404 reservoir for malaria (Andolina et al., 2021; Lindblade et al., 2013) in these regions. Hence, ad-
405 ditional data needs to be collected on polygenomic relatedness across diverse epidemiological
406 settings. These co-transmitted recombinant parasites are more related to each other than para-
407 sites from different mosquito bites, potentially resulting in a further reduced number of different
408 *var* genes sequenced and identified (Wong et al., 2022; Nkhoma et al., 2020; Wong et al., 2017).
409 Low or variable parasite densities resulting from small blood volumes, genomic DNA quality, clin-
410 ical status, and/or within host dynamics, including synchronicity will all create sampling problems
411 (Peyerl-Hoffmann et al., 2001; Bruce et al., 2000; Okell et al., 2012; Farnert et al., 1997; Färnert
412 et al., 2008; Barry et al., 2021; Hergott et al., 2024). But these issues are common to all measures
413 of MOI, as well as to all direct measures of FOI. Our previously proposed framework of MOI esti-
414 mation could be extended in the future to account for these confounding effects in recovering the
415 number of co-infecting strains.

416 A salient characteristic of malaria transmission is the saturation in FOI at high transmission,
417 and the highly non-linear relationship between FOI and another central epidemiological measure
418 related to transmission intensity, the entomological inoculation rate, EIR. Whereas EIR can reach
419 values up to a few hundred or even a thousand per year, the annual FOI saturates rapidly and
420 is typically kept below a limit of 20 (Smith et al., 2010). Although different choices are made on
421 the way EIR and FOI are measured in the field, these cannot account for such drastically differ-
422 ent magnitudes of the two quantities. For example, adults are used as bait to attract and trap
423 mosquitoes, but the attack rates are typically evaluated in children, and there is an observed cor-
424 relation between body size and biting rates. Transmission is highly inefficient in high-transmission
425 endemic regions with high annual EIRs. Because FOI refers directly to detectable blood-stage infec-
426 tions whereas EIR concerns human-vector contact rates, the difference between these quantities is
427 mediated primarily by immunity, or within-host dynamics, measurement bias, and heterogeneous
428 transmission (Donovan et al., 2007; Macdonald, 1950; John et al., 2005; Doolan and Martinez-Alier,
429 2006). The probability of transmission from an infectious mosquito bite is commonly used in math-
430 ematical models to mediate the difference between the two transmission quantities, as a general
431 parameter encapsulating a variety of processes. Though historically paired EIR and FOI values are
432 only available from regions under frequent sampling schemes, our methods, when applied to ge-
433 ographical locations under sparse sampling schemes, could generate further information on this

434 relationship and in so doing, provide further insights into within-host dynamics.

435 The saturation of FOI underlies the challenge of control and elimination efforts and the as-
436 sociated resilience of the transmission system, whereby relaxation of intervention leads to rapid
437 rebounds in prevalence in high-transmission regions. In such regions of high EIR and FOI satura-
438 tion, intervention efforts need to sufficiently reduce EIR to bring FOI below saturation. Only then
439 further intervention efforts would have a significant impact by reducing the number of effective
440 infections which advance to the blood stage. This apparent inefficiency of malaria transmission
441 highlights why high-coverage interventions are often needed to achieve small observable impacts
442 on individual exposure risk. Theory suggests a sharp nonlinear transition towards sustainable low
443 transmission or elimination, including in a recent mathematical model highlighting the role of the
444 high antigenic diversity of *P. falciparum* in high transmission (*de Roos et al., 2023*). The same molec-
445 ular information used here to estimate MOI and FOI in Bongo District underlies such diversity. Our
446 recent modeling work with the agent-based model on the resurgence dynamics of the transmis-
447 sion system below the saturation regime found that local systems can be highly resilient, and can
448 compensate for the reduction in FOI following intervention with the heterogeneity in the duration
449 of infection and more importantly the selection for infections with longer duration (*Zhan et al.,*
450 *2024*). As a result, local systems can maintain during intervention the high prevalence and MOI
451 levels comparable to original values.

452 The proposed methods are generally relevant to evaluate transmission intensity in many pathogens
453 exhibiting multi-genomic infection as the result of large antigenic diversity including those encod-
454 ing such variation by multigene families (*Deitsch et al., 2009*). More easily estimating changes
455 in transmission intensity should contribute to the efficiency and evaluation of control programs
456 across a wider range of infectious diseases.

457 **Materials and Methods**

458 **High genetic diversity of *var* and the associated strain structure of limiting similar-** 459 **ity**

460 We present briefly here aspects of the biology of the malaria parasite *P. falciparum* that constitute
461 the basis for the MOI estimation method used here to then apply the proposed FOI inference.

462 Individual human hosts acquire malaria infections through the infectious bites of mosquitoes,
463 the rate of which can be either fairly constant or seasonal. In high-transmission endemic regions,
464 individual human hosts remain susceptible to malaria re-infection (but not clinical disease) through-
465 out their lifetime (*Doolan et al., 2009*). Indeed, the prevalence of asymptomatic infections is high
466 within adults and older age groups in high-transmission regions, and these infections constitute
467 a large transmission reservoir (*Andolina et al., 2021; Lindblade et al., 2013*). High asymptomatic
468 infections result not only from high transmission rates, but also from hosts' incomplete specific
469 immunity conferred by high antigenic variation of the parasite (*Deitsch et al., 2009*).

470 A common strategy for immune evasion among parasites that exhibit such high asymptomatic
471 prevalence under high transmission is to encode important variant surface antigens (VSAs) with
472 multigene families (*Deitsch et al., 2009*). One important multigene family in the malaria parasite
473 *P. falciparum* known as *var* encodes for the major VSA during the blood stage of infection, PfEMP1
474 (*Plasmodium falciparum* erythrocyte membrane protein 1) (*Zhang and Deitsch, 2022; Baruch et al.,*
475 *1995; Smith et al., 1995; Su et al., 1995*). Each parasite carries 50-60 *var* genes across its 14 chromo-
476 somes and these encode different variants of this protein. Parasites express these genes largely
477 sequentially. Under high-transmission settings, the local parasite population exhibits a large pool
478 of *var* gene variants documented to reach thousands to tens of thousands (*Day et al., 2017; Tiedje*
479 *et al., 2022*). This high level of diversity is enabled primarily by ectopic (mitotic) and meiotic re-
480 combination but also mutation (*Claessens et al., 2014; Frank et al., 2008; Freitas-Junior et al.,*
481 *2000; Bopp et al., 2013*). Migration can also introduce new variants and contribute to the extensive
482 diversity of a local population. Negative frequency-dependent selection (NFDS) mediated by the

483 acquisition of specific immunity by hosts contributes to the maintenance of such a high *var* gene
484 diversity, and to parasite population structure, with individual genomes (or strains or repertoires),
485 and sets of genomes infecting different hosts (or isolates), exhibiting no, or extremely low, overlap
486 of *var* gene composition. This pattern of limiting similarity has been shown to be both non-random
487 and non-neutral (*Day et al., 2017; He et al., 2018*).

488 As hosts typically have not seen many of the VSAs within a single strain, or across different
489 circulating strains, infection duration lengthens which increases the fitness of the parasite by in-
490 creasing its chance of getting transmitted (*Ruybal-Pesántez et al., 2022*). Multi-genomic infection
491 is common, with infections within individual hosts consisting of different parasite clones that have
492 arrived successively via different mosquito bites (superinfection) or simultaneously via one single
493 mosquito bite containing multiple clones (co-transmission) (*Portugal et al., 2011; Nkhoma et al.,*
494 *2020; Wong et al., 2017; Volkman et al., 2012; Anderson et al., 2000a*). The duration of an infec-
495 tion is influenced by the overlap between the constituent *var* genes of that infection and the im-
496 munological memory of the infected host. The measured duration of an individual infection with *P.*
497 *falciparum* in similar settings from empirical observations has been reported to be highly variable
498 (*Childs and Buckee, 2014; Chang et al., 2016; Ashley and White, 2014; Bretscher et al., 2011*).

499 Empirical sequencing of *var* genes specifically concerns the DBL α tag, a small conserved ~450bp
500 region within *var* genes which encodes for the immunogenic Duffy-binding-like alpha domain of
501 PfEMP1 (*Tiedje et al., 2023; Ruybal-Pesántez et al., 2017, 2022; Day et al., 2017*). Bioinformatic
502 analyses of a large database of exon 1 sequences of *var* genes showed a predominantly 1-to-1
503 DBL α -*var* relationship, such that each DBL α tag typically represents a unique *var* gene (*Tan et al.,*
504 *2023*). We use DBL α and *var* interchangeably hereafter.

505 **Bayesian approach to MOI estimation with "varcoding"**

506 The low to non-existent overlap of *var* repertoires enables estimation of MOI on the basis of the
507 number of non-upsA DBL α types sequenced from an individual's isolate. The original method uses
508 a constant repertoire length or number of non-upsA DBL α types in a parasite genome to convert
509 the number of types sequenced in an isolate to the estimated MOI. As such, the method does
510 not take into account the measurement error (Appendix 1-Figure 5D) in this length introduced
511 by the sampling of *var* genes in an infection. We recently extended the method to a Bayesian
512 formulation that does consider this error and provides a posterior distribution of MOI values for
513 each sampled individual (*Tiedje et al., 2023*). We have previously documented the major steps of
514 the Bayesian approach, compared two ways of obtaining an MOI distribution at the population level
515 (either pooling the maximum a posteriori MOI estimates or calculating a mixture distribution), and
516 examined the impact of different priors on the final MOI distribution at the population level. We
517 provide in our analyses hereafter the estimated MOI distribution at the population level obtained
518 from a mixture distribution and using an uniform prior for individuals.

519 We include an evaluation of this Bayesian *varcoding* approach in Appendix 1-A comparison
520 between the performance of the Bayesian approach and the original *varcoding* method from the
521 simulation output.

522 **The under-sampling of infections in estimates of MOI from empirical surveys**

523 The empirical MOI estimates in many epidemiological studies, including ours in Bongo District from
524 northern Ghana, rely on individuals who are microscopy-positive (*Tiedje et al., 2023, 2022*). Given
525 the sensitivity of microscopy, a significant fraction of individuals who carry infections are not de-
526 tected. A subset of the Ghana surveys includes in addition submicroscopic infections detected by
527 PCR (*Tiedje et al., 2023, 2022*). PCR is considerably more sensitive than microscopy, detecting a
528 higher fraction, if not 100%, of individuals with *P. falciparum* infections. Using surveys for which
529 both microscopy and PCR detection were used, we estimated a conversion factor between the pro-
530 portion of hosts that are microscopy-positive and those that are PCR-positive within the targeted
531 age group, i.e., children of 1-5 years old, which is 0.711329.

532 For surveys with available detection by both microscopy and PCR, we can directly calculate the
533 number of individuals with undetected infections by microscopy, i.e., individuals who are microscopy-
534 negative but PCR-positive. For surveys with detection only via microscopy, we use the estimated
535 conversion factor to estimate the number of individuals who are microscopy-negative but PCR-
536 positive. In addition, because the underlying sensitivity of PCR is high but not exactly known, we
537 assume it varies within a reasonable range of values, from a relatively low detectability, i.e., 10%
538 of all PCR-negative individuals carrying undetected infections, to a high and perfect detectability,
539 i.e., none of PCR-negative individuals carrying undetected infections. We calculate the number of
540 individuals with undetected infections by PCR for each sensitivity value respectively.

541 After calculating the number of individuals with undetected infections, including those who
542 are microscopy-negative but PCR-positive and those who carry infections but are PCR-negative,
543 we then sample values from the existing MOI estimates of microscopy-positive individuals who
544 are not under antimalarial treatment (see the following section) to represent those missing MOI
545 estimates.

546 In addition to the detection limit of microscopy and PCR, a fraction of microscopy-positive in-
547 dividuals may not have their *var* information sequenced and typed successfully due to factors in-
548 cluding low DNA quality. Similarly, we sample values from the existing MOI estimates who are not
549 under antimalarial treatment to represent those missing MOI estimates.

550 **Antimalarial drug treatment of infections in estimates of MOI from empirical sur-** 551 **veys**

552 In addition to the missing data error described in the previous section, individuals can also seek and
553 get antimalarial treatment in response to symptoms or the perception of transmission risk. In our
554 field surveys from northern Ghana, more than 50% of children (1-5 years) responded that they had
555 received an antimalarial treatment in the previous two-weeks (i.e., participants that reported they
556 were sick, sought treatment, and were provided with an antimalarial treatment) prior to their blood
557 samples being collected for the wet/high-transmission survey before IRS (i.e., Survey 1, Appendix 1-
558 Figure 5E) (*Tiedje et al., 2022*). In contrast, the fraction is much lower for the dry/low-transmission
559 survey before IRS or for the surveys collected right after IRS (i.e., Appendix 1-Figure 5E) (*Tiedje*
560 *et al., 2022*).

561 To bound reality, which here is difficult if not impossible to determine, given the complexity
562 of the biology, we consider two opposite extremes. For the first one (assumption 1), we assume
563 that antimalarial treatment has no impact on treated individuals' infection status and MOI values.
564 For the second one (assumption 2), we assume that antimalarial treatment affects infection status
565 and MOI values in treated individuals. Thus, we remove the corresponding samples for treated
566 individuals, and implement a bootstrap imputation approach based on the remaining population.
567 We specifically sample values from the MOI estimates of microscopy-positive individuals who are
568 neither under the aforementioned missing data error nor treated, to replace and represent MOI
569 estimates for the treated individuals. This correction takes care of individuals who have used drugs
570 and show either no infection (MOI=0) or infection (MOI>0). We show with numerical simulations
571 that our bootstrap imputation approach is robust to considerable fractions of individuals treated,
572 comparable to those from our survey in Ghana. Reality should lie somewhere in between these
573 two assumptions, with antimalarial treatment affecting the infection status and MOI estimates in
574 some individuals significantly but not in others.

575 The final distribution of MOI estimates at the population level, which includes values for microscopy-
576 positive individuals, the imputed values for individuals with missing MOI information or the false
577 negative individuals, the imputed values for individuals under malarial treatment (applicable for
578 assumption 2), and the true zeros for uninfected individuals, is used for FOI inference.

579 **Empirical surveys from Ghana**

580 For this investigation we rely on empirical data collected from an interrupted time-series study
581 in Bongo District northern Ghana, involving four age-stratified cross-sectional surveys of ~2,000
582 participants per survey between 2012 and 2016. This study was undertaken to investigate the im-
583 pacts of a transient three-round IRS intervention, in combination with long-lasting insecticidal nets
584 (LLINs), on the asymptomatic *P. falciparum* reservoir (*Tiedje et al., 2017, 2022, 2023*). The surveys
585 were undertaken either at the end of the wet/high-transmission season (i.e., October) or at the
586 end of the dry/low-transmission season (i.e., May/June). Additionally the study can be separated
587 into two distinct study phases: (1) Pre-IRS: two surveys prior to the IRS intervention (Survey 1 Octo-
588 ber 2012; Survey 2 May/June 2013); and (2) Right post-IRS: two surveys immediately following the
589 three-rounds of IRS (Survey 3 October 2015; Survey 4 May/June 2016) (Appendix 1-Figure 5E). De-
590 tails on the study area/population, study design, malaria control interventions (i.e., IRS and LLINs),
591 inclusion/exclusion criteria, data collection/generation procedures, routine surveys on whom in
592 the population having taken antimalarial treatment in a previous window of time etc. have been
593 previously described (*Tiedje et al., 2017, 2022, 2023*).

594 **Inferring FOI from MOI estimates**

595 Mathematical consideration of malaria transmission in relation to queuing theory
596 Mathematical models often consider that in a cohort of uninfected people acquiring and clearing
597 infections independently, inoculations arrive according to a homogeneous Poisson process with
598 rate equal to the mean FOI, with each inoculation exhibiting an exponentially distributed duration.
599 It follows that at equilibrium, MOI is a Poisson variable with mean given by the mean FOI divided by
600 the mean clearance rate (*Dietz et al., 1974*). In empirical settings, the arrival of inoculations often
601 deviates from a homogeneous Poisson process due to various factors including seasonality and
602 heterogeneity in exposure risk. Under heterogeneous biting of different hosts, the MOI distribution
603 can be captured by a negative binomial distribution to account for a higher variance. There is
604 no simple relationship in this case, however, between the parameters of the negative binomial
605 distribution and the mean FOI and mean clearance rate. We perform a formal test for any deviation
606 from Poisson homogeneity of the empirical and simulated MOI estimates, with details and results
607 of the test provided in Appendix 1-Test of deviation from Poisson homogeneity in MOI estimates
608 and supplementary file 3-deviationFromPoissonTest.xlsx.

609 Despite these complexities, the process of acquisition of infectious bites is structurally equiva-
610 lent to stochastic queuing theory, which aims to explain how the length of a queue is related to the
611 intensity of arrivals to the system, the systems' priority schedule, and the service and waiting times.
612 Queuing theory is indeed widely employed across multiple applications including in communica-
613 tions, computer architecture, and operation management. The queuing system is usually modeled
614 by a system of differential equations (with the Kolmogorov equations). Their structure depends on
615 specific assumptions of the model, for example, single server vs. multiple servers, stationary vs.
616 non-stationary arrivals, different priority schedules, and so on. The three main information compo-
617 nents of a queuing system are the length of the queue, the intensity of arrivals to the system, and
618 the service times, all of which are coupled. In theory, knowing any two components would allow
619 inference about the third. A simple quantitative description of the process of malaria transmission
620 would be analogous to customers arriving to, and departing from, a service facility. In other words,
621 each individual host is equivalent to a service facility center with a given number of servers, i.e. the
622 carrying capacity for blood-stage infections in the parasite. Moreover, each infection is equivalent
623 to a customer, with infections arriving at an individual host over time and each infection lasting a
624 given amount of time before clearance. The empirical MOI estimates provide information about
625 the length of queues. Hypothetically, when the duration of infection is known, one could infer
626 backwards the information about the rate of arrival of infections to individuals, in other words, the
627 FOI.

628 However, the duration of a single infection is difficult to determine in field samples from en-

629 demic areas, where mono-clonal infections are rare but multi-genomic infections are common.
630 Commonly-used polymorphic markers may not have a high power to differentiate different strains
631 that are co-infecting individual human hosts (*Argyropoulos et al., 2023*). Reasons include that the
632 diversity of those polymorphic markers can be limited, with two parasites sharing the same marker
633 but having distinct sets of antigen-encoding genes. It is thus difficult to accurately measure the
634 emergence and absence from the peripheral blood of any individual strain. Because *var* genes fre-
635 quently undergo ectopic recombination and change the location of their homology blocks on dif-
636 ferent chromosomes across the genome, it is difficult to assign *var* genes to an individual genome
637 and to a specific chromosomal location. The difficulty of phasing precludes the integrity of individ-
638 ual infections and thus the ability to isolate these, as well as the tracking of their corresponding
639 first appearance in the blood and their clearance in time. Also, the duration of infection measured
640 in field studies is highly variable. Examples include infections within individuals of different age
641 groups and therefore different immune histories, but also infections from different geographical
642 locations and times and thus circulating under different transmission intensity and different ge-
643 netic diversity (*Childs and Buckee, 2014; Chang et al., 2016; Ashley and White, 2014; Bretscher
644 et al., 2011*).

645 We therefore propose the alternative strategy of focusing on the MOI estimates of the youngest
646 age group in the population, that is, on those of the 1-5 year-old children. Because these children
647 have received a much lower number of infections than the rest of the population, they have not yet
648 seen much of the circulating diversity. It is thus safe to consider negligible the impact of immune
649 memory accumulated from previous infections on the duration of a current infection. Therefore,
650 infection duration in these children can be approximated by that of naive hosts. Estimates of the
651 latter are available from a historical medical intervention in which patients with neurosyphilis were
652 infected with malaria as a therapy. Between 1940 and 1963, 318 patients with syphilis were inten-
653 tionally infected with a single strain of *P. falciparum* (*Collins and Jeffery, 1999; Maire et al., 2006*).
654 Data on fever and the number of malaria parasites in the blood were recorded. Because those pa-
655 tients had never been infected with *P. falciparum* malaria prior to the treatment, the documented
656 infection duration is representative of naive infections, and can serve as a proxy for infection du-
657 ration in young children. With MOI estimates and the duration of infection at hand, we can then
658 infer the FOI experienced by these children using methods from queuing theory as described next.
659 An additional motivation for focusing on 1-5 year-old children is that they are the most vulnera-
660 ble group of individuals in the population, for whom mortality, severe and clinical cases are most
661 prominent.

662 A two-moment approximation for a queue of finite capacity

663 Analysis of multi-server models in general is notoriously difficult. Exact results are only available
664 for some special models, including the previously mentioned $M/M/c/k$ ones which require that
665 both the inter-arrival times and service times are exponentially distributed. Additional examples of
666 those special models include the $M/G/c/c$ (including the infinite-server $M/G/\infty$) and $GI/M/c/c+r$
667 queues which require that either the inter-arrival times or the service times are exponentially dis-
668 tributed. As such, those special models are often too restrictive to apply to real-world queuing
669 situations in which arrivals do not follow a homogeneous Poisson process (i.e., for which the inter-
670 arrival and service times are not exponentially distributed). Application of a two-moment approxi-
671 mation method is examined here for the steady state analysis as proposed by Kim and Cha (*Choi
672 et al., 2005*), which considers the inter-arrival and service times as independent sequences of inde-
673 pendent and identically distributed (i.i.d.) general random variables (r.v.'s). The approximations are
674 obtained by replacing unknown arrival- and departure-average quantities by their corresponding
675 (well-known) time-average counterparts, which are exact for exponential inter-arrival and service
676 times. More mathematical details and derivations can be found in Appendix 1-The mathematical
677 details for a two-moment approximation for a queue of finite capacity.

678 We vary here the mean and variance parameters for inter-arrival times across wide ranges. For

679 each combination of a specific mean and variance value, we calculate a probability density distribu-
680 tion for the queue length, i.e., a probability density distribution of MOI. We identify the combination
681 of mean and variance values that maximizes the likelihood of observing the given distribution of
682 MOI estimates in either the simulation output or the empirical data from Bongo District. We pro-
683 vide the details for deriving confidence intervals for the estimated mean and variance in Appendix
684 1-Confidence intervals for mean and variance.

685 In the empirical settings with seasonal transmission and heterogeneous exposure risks, the
686 inter-arrival times of infection are likely to be complex and heterogeneous in time. By applying
687 this two-moment approximation method, we treat those inter-arrival times as if they followed a
688 general distribution of any kind with a specific mean and a specific variance to be inferred, and
689 consider consecutive infections independent. Those assumptions are general and flexible enough
690 to be applicable to a variety of empirical settings.

691 Finally, because the goal of this work is to utilize widely available MOI estimates sampled under
692 sparse schemes across geographical space and time, alternative approaches such as fitting a non-
693 homogeneous Poisson process or Gamma process to derive time-varying average arrival rates
694 cannot be considered due to their requirements for densely sampled time-series data.

695 When applying this approach, one needs to specify values for the number of parallel servers (c)
696 and the number of waiting places (r). The former corresponds to the maximum number or carrying
697 capacity of blood-stage infections. The maximum MOI observed in the empirical data from Bongo
698 is 20. Due to additional factors which result in a reduced number of *var* genes sequenced and
699 typed but are not explicitly accounted for in current MOI estimation (see Discussion), the actual
700 carrying capacity could be higher. For simplicity, we assume it to be 30 in the simulation. Without
701 loss of generality, the chosen value for this quantity should not raise any issues for FOI inference
702 based on simulation output, as long as one keeps it consistent when generating simulation output
703 and when applying the two-moment approach to the simulation output. For FOI inference based
704 on the empirical surveys from Bongo, we set this quantity to be either 25 or 30. Because the results
705 of FOI inference are robust against those two values, we report the one with $c = 30$. Because FOI
706 represents the number of effective infections which reach the blood stage and MOI is defined for
707 blood-stage infections only, by default, the number of waiting places r should be set to be 0.

708 The mean arrival rate of infection from Little's law

709 The second method is known as Little's law (**Little and Graves, 2008**), which describes a relationship
710 between the three main information components of queuing systems. This law states that the
711 average number of items in a queuing system L equals the average arrival rate λ multiplied by the
712 average waiting time of an item in the system, W . Reformulating Little's law in terms of malaria
713 transmission, the average arrival rate of infection λ equals the average number of blood-stage
714 active infections present in an individual L divided by the average duration of infection W .

$$\lambda = \frac{L}{W} \quad (1)$$

715 The relationship is remarkably simple and general. It requires that in the long run the average
716 number of arrivals is less than or equal to the average number of exits, such that the queue does
717 not overflow. The law applies however irrespective of the number of servers (here, the carrying
718 capacity of blood-stage infections of hosts), the service time distribution (here, infection duration
719 distribution), the distribution of inter-arrival times, the order of items' service, and whether each
720 server has its own queue or a single queue feeds all servers. In theory, individual human hosts
721 can experience "overflowing" under high-transmission settings with high EIR values, but evidence
722 has suggested that the majority of these infectious bites do not result in detectable blood-stage
723 infections. Because FOI by definition represents the rate of arrival of effective infections acquired
724 by human hosts that have advanced to the blood-stage, and not the rate of arrival of all infections
725 (which is known as EIR), we consider that the requirement approximately applies in the context

of FOI inference for malaria transmission. In other words, values of FOI do not include and hence should not be influenced by the loss of excessive arrivals due to various factors including immunity, measurement bias, and so on.

Little's law holds for an evolving time series as it is observed over a long period of time. Although we do not have time series of MOI estimates for any individual host, we treat different sampled individual hosts as if each one represented an observation of the process at a single time point. This is sensible because different individual hosts are likely to receive infections in an asynchronous manner, and therefore, the aggregation of MOI information across different individual hosts can function as a proxy for a time series of MOI values for an individual host.

Conversion between FOI and the Entomological Inoculation Rate, or EIR

As an indirect proxy for transmission intensity, malariologists typically measure EIR by counting how many infectious bites are received within a time interval by a human host seated in a fixed place (*Shaukat et al., 2010*). The resulting value of EIR is considered a standard metric of malaria transmission. Though FOI and EIR both reflect transmission intensity, the former refers directly to detectable blood-stage infections whereas the latter concerns human-vector contact rates. Studies reporting both the annual *P. falciparum* EIR and FOI estimates from detailed age-stratified prevalence in cross-sectional parasitological studies, have obtained very different magnitudes for these two quantities (*Smith et al., 2010*). We refer here to the number of infections (in the blood stage) per infectious bite (FOI/EIR) as transmission efficiency. Several studies have shown that malaria transmission is inefficient in high-intensity settings, and there has been a long-standing debate on the reason why. Heterogeneous biting, immunity, or measurement bias have been proposed as causes for explaining this discrepancy between EIR and FOI (*Donovan et al., 2007; John et al., 2005; Doolan and Martinez-Alier, 2006; Smith et al., 2010*). Within host competition for resources between co-infecting strains and the resulting dominance of a subset of those strains, with the remaining others at low parasitemia, can also account for this discrepancy. Parasites may not be transmitted from an infectious mosquito to a human during the blood meal due simply to chance. We borrow a functional curve with estimated parameters under the assumption of heterogeneous transmission, which describes the highly non-linear relationship between these reported EIR-FOI pairs (*Smith et al., 2010*). The functional curve is in the format of the following equation with h denoting FOI and E denoting EIR. The corresponding parameters are as follows: $b = 0.55$, $\alpha = 4.6$ and $t = 43$ days.

$$h = \frac{\log(1 + \alpha b E t)}{\alpha t} \quad (2)$$

The combination of these reported EIR-FOI pairs (*Smith et al., 2010*) and the functional curve provides a basis for converting from one quantity to the other.


The EIR information for a subset of surveys in Bongo District from northern Ghana was obtained (*Tiedje et al., 2022*). Together with the FOI estimates from the two methods from queuing theory, we have the EIR-FOI pairs for empirical surveys in Bongo District. Therefore, we can address whether our EIR-pairs are consistent with those previous historical collections of EIR-FOI pairs and the functional curve with the best-fit parameter values to those collections.

Appendix

The measurement error


We utilize a measurement error model in MOI estimation which accounts for the under-sampling or imperfect detection of *var* genes by sub-sampling *var* genes per strain, thus reducing the number of available distinct *var* genes per host. This measurement error model is based on the repertoire size distribution. The molecular sequences used for deriving the repertoire size distribution were previously sequenced from infections that are expected to be monoclonal (MOI = 1), i.e., hosts infected by a single *P. falciparum* strain, as they had less than or equal to 45 non-upsA DBL α types,

772 sampled during six cross-sectional surveys made from 2012 to 2016 in Bongo District from north-
 773 ern Ghana (Appendix 1-Figure 5D) (Tiedje et al., 2023, 2022; Pilosof et al., 2019).




774

Figure 5. (A) Each simulation follows three stages: a “pre-IRS” period during which the transmission in the local population reaches a stationary state, followed by an “IRS” intervention period of three years which reduces transmission rate (in what we call transient IRS), and a “post-IRS” period when transmission rates go back to their original levels. We let the system run for some years to reach a (semi-) stationary state before applying IRS interventions. After initial seeding, closed systems do not receive migrant genomes from the regional pool. Semi-open systems are explicit simulations of two individual local populations coupled via migration events. Regionally-open systems receive continuous migrant genomes from the regional pool throughout the simulation course. (B) Transmission intensity or effective contact rate (Appendix 1-Simulation data) varies as a function of time, from pre-, to during, to post-intervention. We simulate three different coverages of perturbations, ranging from low-coverage one which reduces the system’s transmission by around 20% to high-coverage one which reduces the system’s transmission by around 70-75%. (C) We incorporate heterogeneity in transmission across individual hosts by varying two things. First, we consider different statistical distributions for times of local transmission events: exponential and Gamma. Second, we consider homogeneous and heterogeneous exposure risks. For the latter, we set $\frac{2}{3}$ of the total population as being at high-risk and receiving more than 90% of all bites whereas the rest population receives only less than 10% of all bites. (D) The measurement error which describes potential sequencing errors of *var* genes: histogram of the number of non-upsA (i.e., upsB and upsC) DBL α *var* gene types per repertoire. The molecular sequences were previously sequenced from infections that are expected to be monoclonal (as they had less than or equal to 45 non-upsA DBL α types), sampled during six cross-sectional surveys made from 2012 to 2016 in Bongo District. (E) Study design showing the timing of the four age-stratified cross-sectional surveys conducted in Bongo District, Ghana at the end of the wet/high-transmission seasons (blue circles) and at the end of the dry/low-transmission seasons (gold circles). The study can be broken down into two phases: (1) Pre-IRS: Survey 1 (S1) October 2012 and Survey 2 (S2) May/June 2013; (2) Right post-IRS: Survey 3 (S3) October 2015 and Survey 4 (S4) May/June 2016. IRS were implemented against a background of widespread LLIN usage which were distributed across Bongo District between 2010 – 2012 and again in 2016 (Tiedje *et al.*, 2023; Gogue *et al.*, 2020).



775

Figure 6. Comparison of the estimated MOI distribution under only one type of error among those commonly encountered in the collection of empirical data (missing data, under-sampling of *var* genes, and usage of antimalarial drugs) versus under all the types of the errors together and the distribution of true MOI values (indicated by different shades of the red). The scenarios shown here are simulated as semi-open systems under seasonal transmission. Individuals are under heterogeneous exposure risk (Appendix 1-Figure 5C) and the arrival of infection follows a Gamma distribution. The Bayesian *var*coding method and the bootstrap imputation approach are able to address all types of the errors. Results of the comparison across other simulated scenarios can be found in supplementary file 1-MOImethodsPerformance.xlsx



776

Figure 7. Comparison of the estimated MOI distribution based on the original *varcoding* method, the Bayesian approach, and the true values. The scenarios shown here correspond to a semi-open system under seasonal transmission. Arrival of infection follows a Gamma distribution. Both the Bayesian *varcoding* approach and the original method perform well, with the former showing a clear improvement in capturing the tail of high MOI values. Results of the comparison across the remaining different simulated scenarios can be found in supplementary file 2-BayesianImprovement.xlsx.

777 **Simulation data**

778 An extended *var* model and experimental designs

779 To evaluate the relative performance of the two proposed methods from queuing theory for FOI
780 inference across different transmission settings, we generate simulation output using a computa-
781 tional model. This model is an extension of an agent-based, discrete-event, stochastic model in
782 continuous time (*He et al., 2018*). The original implementation is adapted from the next-reaction
783 method (*Gibson and Bruck, 2000*) which optimizes the Gillespie first-reaction method (*Gillespie,*
784 *1976*). It tracks the infection history and immune memory of each host. Parameters or symbols,
785 and their values are summarized in the supplementary file 4-simParams.xlsx. We model a local
786 population of 10000 individuals. All simulation runs are initialized with 20 infections to seed local
787 population transmission. We let each simulation run for some years (200 years for closed systems,
788 150 years for open systems) to reach a (semi-) stationary state before introducing transmission-
789 reducing interventions.

790 The size of a single parasite repertoire is assumed to be 45 here, based on the median number
791 of non-upsA DBL α sequences identified in our 3D7 laboratory isolate (*Ruybal-Pesántez et al., 2022;*
792 *Tiedje et al., 2022*). This grouping of *var* genes is defined based on their semi-conserved upstream
793 promoter sequences (ups) (correspondingly for upsA and non-upsA (upsB and upsC)) (*Gardner*
794 *et al., 2002; Lavstsen et al., 2003; Kraemer et al., 2007; Rask et al., 2010*). Although each parasite
795 carries both types of *var* genes in a fairly constant proportion (*Ruybal-Pesántez et al., 2017; Tiedje*
796 *et al., 2023; Ruybal-Pesántez et al., 2022; Buckee and Recker, 2012; Rask et al., 2010*), the MOI es-
797 timation method we consider here focuses on the non-upsA DBL α sequences as they are around
798 20 times more diverse and less conserved among repertoires than the upsA DBL α sequences. Al-
799 though there is evidence indicating functional differences between the two groups, the groupings
800 do not necessarily correlate with function. Within-group functional heterogeneity and variation,
801 and cross-group functional similarity exist (*Claessens et al., 2012; Kaestli et al., 2006; Rottmann*
802 *et al., 2006*). In addition, the mechanism underlying the fairly constant proportion of two struc-
803 tural groups in empirical samples across time and geographical locations remains to be properly
804 understood. It is therefore unclear how to model functional divergence of *var* groups in a rigorous
805 and parsimonious way, and whether assumptions made on the particular coarse-graining apply to
806 the population dynamics of the disease. Therefore, for simplicity purposes, our model considers
807 only one type of gene, corresponding to the non-upsA types.

808 Each *var* gene itself is represented as a linear combination of two epitopes (the parts of the
809 molecule that act as antigens and are targeted by the immune system) (*Bull et al., 2008; Larremore*
810 *et al., 2013; Rask et al., 2010; He et al., 2018*).

811 The *var* genes in a repertoire are expressed sequentially and the infection gets cleared when the
812 whole repertoire is depleted. The duration of expression of a *var* gene is proportional to the num-
813 ber of unseen epitopes by the infected host. The total duration of infection of a particular reper-
814 toire is proportional to the number of unseen epitopes by the infected host aggregated across all
815 individual *var* genes of that repertoire. When a *var* gene is deactivated, the host adds the deacti-
816 vated *var* gene epitopes to its immunity memory. Specific immunity toward a given epitope wanes
817 at a certain rate, and re-exposure is therefore required to maintain it.

818 We simulate malaria dynamics with parameters representative of high-transmission endemic
819 regions, with either constant or seasonal transmission, and across different spatial configurations,
820 including closed, semi-open, and regionally-open systems. We apply perturbations in our model
821 that represent interventions targeting the mosquito vector with indoor residual spraying (IRS) that
822 involves the application of an insecticide to internal walls and ceilings of homes (*World Health Orga-*
823 *nization, 2015*). IRS effectively reduces mosquito population, and therefore, transmission rate and
824 growth rate of the parasite population as a whole. We simulate three temporary IRS interventions
825 of different coverages, ranging from low- to mid- to high- coverage respectively. The low-coverage
826 intervention reduces the system's transmission by around 20%; the mid-coverage one reduces by
827 around 45%; and the high-coverage one reduces by around 70-75%. Each IRS intervention lasts for
828 3 years.

829 Mosquitoes are not represented as explicit agents in the model but their role in transmission
830 is implemented via contact events between human hosts. We consider an effective contact rate
831 (hereafter, the transmission rate or transmission intensity) which determines the times of local
832 transmission events. These times can follow different distributions, including exponential and
833 Gamma ones. At these times, a donor and a recipient host are selected randomly and success-
834 ful transmission occurs only if the donor carries active (blood-stage) infections and the liver stage
835 of the recipient is below a specified carrying capacity of 30.

836 We implemented seasonality by multiplying a scaling constant by a temporal vector of 360 days,
837 containing the daily number of mosquitoes over a full year. In other words, we have a basic vector
838 representing the number of mosquitoes and a scaling constant encapsulating all other parame-
839 ters involved in vectorial capacity. The product of both gives the effective contact rate. To obtain
840 this temporal vector, (*Pilosof et al., 2019*) used a deterministic model for mosquito population dy-

841 namics from (*White et al., 2011*). The model was originally developed for *Anopheles gambiae* and
842 consists of a set of ordinary differential equations describing the dynamics of 4 mosquito stages:
843 eggs, larvae, pupae, and adults. Seasonality is implemented via density dependence at the egg
844 and larva stages as a function of rainfall (availability of breeding sites). The values of the effective
845 contact rate rather than the absolute number of daily mosquitoes are the key parameters for the
846 purpose of this work.

847 For closed systems, after the initial seeding of local transmission from a regional pool of *var*
848 genes, migration is discontinued. Semi-open systems are an explicit simulation of two individual
849 populations coupled via migration. Regionally-open systems are a local population with migration
850 from a regional pool. The regional *var* gene pool of a certain size acts as a proxy for regional
851 parasite diversity, i.e., diversity from the aggregated individual populations in the region. Para-
852 site genomes can migrate from the regional pool to the local population. Because each parasite
853 genome is a repertoire with a given number of *var* genes, migrant genomes are assembled from
854 the random sampling of this number of *var* genes from the regional pool.

855 Transmission can be homogeneous or heterogeneous across individual hosts. For the latter,
856 we consider two groups of human hosts: the high risk group receives more than 90% of the total
857 infection events, whereas the low risk group receives the remaining fraction. The two risk groups
858 have different sizes, and the size of the high-risk group to that of the low-risk one is 2:1.

859 **Test of deviation from Poisson homogeneity in MOI estimates**

860 A great deal of research has addressed the statistical question of whether a count dataset exhibits
861 significant deviation from a homogeneous Poisson distribution. We select the Potthoff-Whittinghill
862 "index of dispersion" test (*Potthoff and Whittinghill, 1966; Lloyd-Smith et al., 2005*), which is asymp-
863 tomatically locally most powerful against the negative binomial alternative. For a dataset X with
864 N elements, this statistic is given by $\frac{(N-1) \cdot \text{var}(X)}{\text{mean}(X)}$ and its asymptotic distribution is chi-squared with
865 $N - 1$ degrees of freedom. A p-value is obtained by determining the cumulative density of the
866 chi-squared ($N - 1$) distribution to the right of the test statistic, and represents the probability that
867 the observed variance arose by chance from a Poisson distribution.

868 We summarize the p-value of the Potthoff-Whittinghill "index of dispersion" test in supplemen-
869 tary file 3-deviationFromPoissonTest.xlsx. The p-values are very close to 0, indicating that the de-
870 viation from a Poisson distribution is highly significant for both simulation output and empirical
871 surveys from Bongo District. A few exceptions are observed when intervention is high-coverage
872 pushing the system's prevalence to be very low and the majority of infections become mono-clonal.

873 **The mathematical details for a two-moment approximation for a queue of finite 874 capacity**

875 Following (*Choi et al., 2005*), we describe here the consideration of the $GI/G/c/c + r$ queue with
876 $c (\geq 1)$ identical servers in parallel and $r (\geq 0)$ waiting places. For an individual host, we consider c
877 carrying capacity in blood stage and $r = 0$ carrying capacity for the waiting space. Inter-arrival and
878 service times of customers are independent sequences of independent and identically distributed
879 (i.i.d.) general random variables (r.v.'s).

880 N represents the number of customers in the system at an arbitrary time. $N^A(N^D)$ denotes the
881 number of customers that an arriving customer finds (that a departing customer leaves behind) in
882 steady state. Customers who arrive to find $c + r$ customers in the system are assumed to depart
883 immediately from the system with those $c + r$ customers left behind. P_n , P_n^A and P_n^D denote the
884 probabilities that $N = n$, $N^A = n$, and $N^D = n$, respectively, for $0 \leq n \leq c + r$.

885 The previous probabilities will be expressed in terms of the following quantities:

$$\begin{aligned} a &= E(A) = \frac{1}{\lambda} \\ b &= E(S) \\ a_n^D &= E[A_n^D], 0 \leq n \leq c+r \\ b_n^A &= E[S_n^A], 0 \leq n \leq c+r \\ b_n^D &= E[S_n^D], 0 \leq n \leq c+r \end{aligned}$$

886 A_n^D with $0 \leq n \leq c+r$ is the residual inter-arrival time at the departure instant of a customer who
 887 leaves behind n customers in the system. $S_n^A(S_n^D)$ with $1 \leq n \leq c+r$ is the residual service time of a
 888 randomly chosen busy server at the arrival instant (the departure instant) of a customer who finds
 889 (leaves behind) n customers in the system.

890 A two-moment approximation for the steady-state queue-length distribution as follows:

$$\begin{aligned} \tilde{P}_n^A &= \tilde{P}_n^D = \tilde{P}_0^A \prod_{i=0}^{n-1} \frac{\tilde{\lambda}_i}{\tilde{\mu}_{i+1}}, 1 \leq n \leq c+r \\ \tilde{P}_n &= \tilde{P}_n^A \tilde{\gamma}_n, 0 \leq n \leq c+r \end{aligned}$$

891 where

$$\frac{1}{\tilde{\mu}_i} = \begin{cases} b - i(a - a_R), 1 \leq i \leq c \\ -c(a - a_R) + b_R, c+1 \leq i \leq c+r \end{cases}$$

$$\frac{1}{\tilde{\lambda}_i} = \begin{cases} (i+1)a_R, 0 \leq i \leq c-2 \\ ca_R + b_R - b, c-1 \leq i \leq c+r-2 \\ ca, i = c+r-1 \end{cases}$$

$$\tilde{\gamma}_i = \begin{cases} \lambda a_R, i = 0 \\ \lambda [\tilde{\mu}_i \frac{(a-a_R)}{\tilde{\lambda}_{i-1}} + a_R], 1 \leq i \leq c+r-1 \\ \lambda [\tilde{\mu}_i \frac{(a-a_R)}{\tilde{\lambda}_{i-1}} + a], i = c+r \end{cases}$$

892 And, by normalization, $\sum_{n=0}^{c+r} \tilde{P}_n^A = 1$:

$$\tilde{P}_0^A = (1 + \sum_{n=1}^{c+r} \prod_{i=0}^{n-1} \frac{\tilde{\lambda}_i}{\tilde{\mu}_{i+1}})^{-1}$$

893 Confidence intervals for mean and variance

894 Non-parametric bootstrap

895 Bootstrap datasets were generated by resampling with replacement from the original data. For
 896 each bootstrap dataset, the maximum likelihood estimates of the mean and the variance of FOI
 897 were determined, generating a bootstrap sampling distribution. We ran 200 bootstrap replicates
 898 because this number has been tested and proven to approach a similar coefficient of variation
 899 than a higher number of replicates (*Efron and Tibshirani, 1994*).


900 **A comparison between the performance of the Bayesian approach and the original**
901 ***var*coding method from the simulation output**

902 We compare the performance of the original *var*coding method and the Bayesian formulation for-
903 mally against true MOI values with a Kolmogorov-Smirnov Test. Specifically, we calculate the maxi-
904 mum vertical deviation between the two cumulative density function of MOI distribution obtained
905 from either of the two methods against each other, and each against true values respectively. Ad-
906 ditionally, we compare the mean value of MOI estimates obtained from the two methods and true
907 MOI.

908 The Bayesian method shows improvement relative to the original *var*coding method which re-
909 lies on a constant repertoire size to convert the number of detected non-upsA DBL α types to the
910 estimated MOI value. We document the Kolmogorov-Smirnov statistics and the difference in the
911 mean values of MOI estimates in supplementary file 2-BayesianImprovement.xlsx. This improve-
912 ment is expected given consideration of variation in repertoire size due to the under-sampling of
913 *var* genes. Both methods perform well for low or mid transmission scenarios (corresponding to
914 high- or mid-coverage intervention scenarios respectively) when the majority of true MOI centers
915 around low or intermediary values. The *var*coding method has decent performance for high trans-
916 mission scenarios, with the Bayesian method showing further notable improvement in capturing
917 the tail of high MOI values. The Bayesian method improves estimation accuracy for high MOI val-
918 ues in particular because the cumulative effect of the measurement error for multiple infections
919 becomes more significant. In high-transmission endemic regions, a higher fraction of infected indi-
920 viduals harbors more infections, and thus have higher MOI values. The improvement can be more
921 evident for these regions, including Bongo District, Ghana for which we obtained our empirical MOI
922 estimates.

923 Both the Bayesian and the original version of *var*coding approach tend to underestimate MOI
924 (see Discussion). Overall, the distribution of the estimated MOI from both methods is quite sim-
925 ilar to that of the true MOI, across all simulated scenarios. The Bayesian MOI estimation is fairly
926 accurate and robust in addressing the under-sampling of *var* genes error. Nevertheless, we note
927 that the proposed approaches for estimating FOI can be based on MOI values obtained with any
928 method and any polymorphic marker other than the *var* multigene family.


929



930

Figure 8. The distribution of MOI estimates based on the Bayesian *var*coding method and the bootstrap imputation approach for longitudinal surveys in Bongo District, from pre-IRS to right post-IRS. See Appendix 1-Figure 5E for the study design of the IRS intervention. The wet/high season survey for pre-IRS phase was collected in 2012 and denoted as S1 in Figure 5E. The dry/low season survey for pre-IRS phase was collected in 2013 and denoted as S2. The wet/high season survey for right post-IRS phase was collected in 2015, corresponding to S3. The dry/low season survey for right post-IRS phase was collected in 2016 and denoted as S4. As explained in the methods, the empirical surveys suffer from missing data, i.e., only microscopy-positive individuals have their *var* genes typed and sequenced. We quantify the number of individuals with missing MOI by utilizing the empirically measured detectability/sensitivity of microscopy relative to PCR, and assuming a range for the PCR detectability. We consider a high detectability in which PCR picks up all infected individuals, to a mid value in which 5% PCR-negative individuals actually carry infections, to a low value in which 10% PCR-negative individuals carry infections. The empirical surveys also suffer from missing data due to other factors than the detection limit of the selected method, for example, low DNA quality. We impute MOI values for all those individuals with missing MOI by sampling from MOI estimates of microscopy-positive individuals with their *var* sequenced and typed successfully who are not treated. In addition, some individuals may seek and get antimalarial treatment in a previous window of time. We consider here the extreme scenario that antimalarial treatment has no impact on treated individuals' infection status and MOI values, and use their infection status and MOI values directly for FOI inference.


931



932

Figure 9. The distribution of MOI estimates based on the Bayesian *var*coding method and the bootstrap imputation approach for longitudinal surveys in Bongo District, from pre-IRS, to right post-IRS, to post-IRS/SMC. We assume here the other extreme scenario that antimalarial treatment shifts and changes treated individuals' infection status and MOI values completely. We thus impute MOI values for those treated individuals by sampling from MOI estimates of microscopy-positive individuals with their *var* sequenced and typed successfully who are not treated.


933



934

Figure 10. The true and estimated FOI by the two-moment approach and Little's law for additional simulated homogeneous exposure risk scenarios, under non-seasonal transmission, for a closed system. The times of the local transmission events are Gamma-distributed. The true mean FOI per host per year is calculated by dividing the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.


935



936

Figure 11. The true and estimated FOI by the two-moment approach and Little's law for simulated heterogeneous exposure risk scenarios under non-seasonal transmission in a semi-open system. The times of the local transmission events are Gamma-distributed. The true mean FOI per host per year is calculated by dividing the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.


937



938

Figure 12. The true and estimated FOI by the two-moment approach and Little's law for simulated homogeneous exposure risk scenarios under seasonal transmission in a regionally-open system. The times of the local transmission events are Gamma-distributed. The true mean FOI per host per year is calculated by dividing the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.


939



940


Figure 13. The true and estimated FOI by the two-moment approach and Little’s law for simulated homogeneous exposure risk scenarios under non-seasonal transmission in a regionally-open system. The times of the local transmission events are Gamma-distributed. The true mean FOI per host per year is calculated by dividing the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.

941



942

Figure 14. The true and estimated FOI by the two-moment approach and Little’s law for simulated homogeneous exposure risk scenarios and seasonal transmission. The spatial setting corresponds to the closed system. The times of the local transmission events follow an exponential distribution. The true mean FOI per host per year is calculated by dividing the total number of infections acquired by the population by the total number of individual hosts in the population. Minimum, 5% quantile, median, 95% quantile, and maximum values are shown in the boxplot.



943

Figure 15. Magnitudes of the estimated variance by the two-moment approximation method for different simulation scenarios and the field data in Bongo District, Ghana.

944

Data and code availability

945

The sequences utilized in this study are publicly available in GenBank under BioProject Number: PRJNA 396962. All additional data associated with this study are available in the main text, the supplementary information, or upon reasonable request to the authors. For information on the simulation code and analysis scripts, please see <https://github.com/qzhan321/FOI>.

946

947

Acknowledgments

948

We wish to thank the participants, communities, and the Ghana Health Service in Bongo District, Ghana for their willingness to participate in the study of empirical data. We would like to thank the field teams in Bongo for their technical assistance in the field, as well as the laboratory personnel at the Navrongo Health Research Centre for their expertise and for undertaking the sample collections and parasitological assessments. This research was supported by Fogarty International Center at the National Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases award R01-TW009670 to K.P.D and M.P.; and the National Institute of Allergy and Infectious Diseases, National Institutes of Health through the joint NIH-NSF-NIFA Ecology and Evolution of Infectious Diseases award R01-AI149779 to K.P.D and M.P. We appreciate the support of the Research Computing Center at the University of Chicago through the computational resources of the Midway cluster.

949

950

References

951

Abukari Z, Okonu R, Nyarko SB, Lo AC, Dieng CC, Salifu SP, Gyan BA, Lo E, Amoah LE. The Diversity, Multiplicity of Infection and Population Structure of *P. falciparum* Parasites Circulating in Asymptomatic Carriers Living in High and Low Malaria Transmission Settings of Ghana. *Genes (Basel)*. 2019; doi: [doi:10.3390/genes10060434](https://doi.org/10.3390/genes10060434).

952

953

954

955

956

957

958

959

960

- 966 **Alonso PL**, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against *Plasmodium falciparum* infec-
967 tion and disease in young African children: randomised controlled trial. *The Lancet*. 2004; 364(9443):1411-
968 1420. doi: [https://doi.org/10.1016/S0140-6736\(04\)17223-1](https://doi.org/10.1016/S0140-6736(04)17223-1).
- 969 **Anderson TJ**, Haubold B, Williams JT, et al. Microsatellite markers reveal a spectrum of population struc-
970 tures in the malaria parasite *Plasmodium falciparum*. *Mol Biol Evol*. 2000; doi: [10.1093/oxfordjour-](https://doi.org/10.1093/oxfordjournals.molbev.a026247)
971 [nals.molbev.a026247](https://doi.org/10.1093/oxfordjournals.molbev.a026247).
- 972 **Anderson TJC**, Haubold B, Williams JT, Estrada-Francoš JG, Richardson L, Mollinedo R, Bockarie M, Mokili J,
973 Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU, Day KP. Microsatellite
974 Markers Reveal a Spectrum of Population Structures in the Malaria Parasite *Plasmodium falciparum*. *Molecu-*
975 *lar Biology and Evolution*. 2000 10; 17(10):1467-1482. <https://doi.org/10.1093/oxfordjournals.molbev.a026247>,
976 doi: [10.1093/oxfordjournals.molbev.a026247](https://doi.org/10.1093/oxfordjournals.molbev.a026247).
- 977 **Andolina C**, Rek JC, Briggs J, Okoth J, Musiime A, Ramjith J, Teyssier N, Conrad M, Nankabirwa JI, Lanke K,
978 Rodriguez-Barraquer I, Meerstein-Kessel L, Arinaitwe E, Olwoch P, Rosenthal PJ, Kanya MR, Dorsey G, Green-
979 house B, Drakeley C, Staedke SG, et al. Sources of persistent malaria transmission in a setting with effective
980 malaria control in eastern Uganda: a longitudinal, observational cohort study. *The Lancet Infectious diseases*.
981 2021; doi: [https://doi.org/10.1016/S1473-3099\(21\)00072-4](https://doi.org/10.1016/S1473-3099(21)00072-4).
- 982 **Argyropoulos DC**, Tan MH, Adobor C, Mensah B, Labbé F, Tiedje KE, Koram KA, Ghansah A, Day KP. Perform-
983 ance of SNP barcodes to determine genetic diversity and population structure of *Plasmodium falciparum*
984 in Africa. *Front Genet*. 2023; doi: [10.3389/fgene.2023.1071896](https://doi.org/10.3389/fgene.2023.1071896).
- 985 **Annot D**. Clone multiplicity of *Plasmodium falciparum* infections in individuals exposed to variable levels of dis-
986 ease transmission. *Transactions of the Royal Society of Tropical Medicine and Hygiene*. 1998; 92(6):580-585.
987 <https://www.sciencedirect.com/science/article/pii/S0035920398907738>, doi: [https://doi.org/10.1016/S0035-](https://doi.org/10.1016/S0035-9203(98)90773-8)
988 [9203\(98\)90773-8](https://doi.org/10.1016/S0035-9203(98)90773-8).
- 989 **Ashley EA**, White NJ. The duration of *Plasmodium falciparum* infections. *Malar J*. 2014; doi: [doi:10.1186/1475-](https://doi.org/10.1186/1475-2875-13-500)
990 [2875-13-500](https://doi.org/10.1186/1475-2875-13-500).
- 991 **Barry A**, Awandu SS, Tiono AB, Grignard L, Bousema T, Collins KA. Improved Detectability of *Plasmodium*
992 *falciparum* Clones with Repeated Sampling in Incident and Chronic Infections in Burkina Faso. *Am J Trop*
993 *Med Hyg*. 2021; doi: [10.4269/ajtmh.21-0493](https://doi.org/10.4269/ajtmh.21-0493).
- 994 **Barry AE**, Leliwa-Sytek A, Tavul L, Imrie H, Migot-Nabias F, Brown SM, McVean GAV, Day KP. Popula-
995 tion Genomics of the Immune Evasion (var) Genes of *Plasmodium falciparum*. *PLoS Pathog*. 2007; doi:
996 <https://doi.org/10.1371/journal.ppat.0030034>.
- 997 **Baruch DI**, Pasloske BL, Singh HB, et al. Cloning the *P. falciparum* gene encoding PfEMP1, a malarial variant anti-
998 gen and adherence receptor on the surface of parasitized human erythrocytes. *Cell*. 1995; doi: [10.1016/0092-](https://doi.org/10.1016/0092-8674(95)90054-3)
999 [8674\(95\)90054-3](https://doi.org/10.1016/0092-8674(95)90054-3).
- 1000 **Beier JC**, Oster CN, Onyango FK, Bales JD, Sherwood JA, Perkins PV, Chumo DK, Koech DV, Whitmire RE, Roberts
1001 CR, Diggs CL, Hoffman SL. *Plasmodium falciparum* incidence relative to entomologic inoculation rates at a
1002 site proposed for testing malaria vaccines in western Kenya. *The American journal of tropical medicine and*
1003 *hygiene*. 1994; doi: <https://doi.org/10.4269/ajtmh.1994.50.529>.
- 1004 **Bekessy A**, Molineaux L, Storey J. Estimation of incidence and recovery rates of *Plasmodium falciparum* para-
1005 sitaemia from longitudinal data. *Bull World Health Organ*. 1976; .
- 1006 **Bopp SER**, Manary MJ, Bright AT, Johnston GL, Dharia NV, Luna FL, et al. Mitotic Evolution of *Plasmodium*
1007 *falciparum* Shows a Stable Core Genome but Recombination in Antigen Families. *PLoS Genet*. 2013; doi:
1008 [10.1371/journal.pgen.1003293](https://doi.org/10.1371/journal.pgen.1003293).
- 1009 **Bretscher MT**, Maire N, Chitnis N, Felger I, Owusu-Agyei S, Smith T. The distribution of *Plasmodium falciparum*
1010 infection durations. *Epidemics*. 2011; doi: <https://doi.org/10.1016/j.epidem.2011.03.002>.
- 1011 **Bruce MC**, Galinski MR, Barnwell JWea. Genetic diversity and dynamics of *plasmodium falciparum* and *P. vi-*
1012 *vax* populations in multiply infected children with asymptomatic malaria infections in Papua New Guinea.
1013 *Parasitology*. 2000; doi: [10.1017/s0031182099006356](https://doi.org/10.1017/s0031182099006356).
- 1014 **Buckee CO**, Recker M. Evolution of the multi-domain structures of virulence genes in the human malaria
1015 parasite, *Plasmodium falciparum*. *PLoS Comput Biol*. 2012; doi: [10.1371/journal.pcbi.1002451](https://doi.org/10.1371/journal.pcbi.1002451).

- 1016 **Bull PC**, Buckee CO, Kyes S, Kortok MM, Thathy V, Guyah B, Stoute JA, Newbold CI, Marsh K. *Plasmodium falciparum* antigenic variation. Mapping mosaic *var* gene sequences onto a network of shared, highly polymorphic sequence blocks. *Molecular microbiology*. 2008; doi: <https://doi.org/10.1111/j.1365-2958.2008.06248.x>.
- 1017
- 1018
- 1019 **Carneiro I**, Roca-Feltre A, Griffin JT, Smith L, Tanner M, Schellenberg JA, Greenwood B, Schellenberg D. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. *PloS one*. 2010; doi: <https://doi.org/10.1371/journal.pone.0008988>.
- 1020
- 1021
- 1022 **Chang HH**, Childs LM, Buckee CO. Variation in infection length and superinfection enhance selection efficiency in the human malaria parasite. *Sci Rep*. 2016; doi: <https://doi.org/10.1038/srep26370>.
- 1023
- 1024 **Chang HH**, Worby CJ, Yeka A, Nankabirwa J, Kanya MR, Staedke SG, Dorsey G, Murphy M, Neafsey DE, Jeffreys AE, Hubbard C, Rockett KA, Amato R, Kwiatkowski DP, Buckee CO, Greenwood B. THE REAL McCOIL: A method for the concurrent estimation of the complexity of infection and SNP allele frequency for malaria parasites. *PLoS Computational Biology*. 2017; doi: <https://doi.org/10.1371/journal.pcbi.1005348>.
- 1025
- 1026
- 1027
- 1028 **Childs LM**, Buckee CO. Dissecting the determinants of malaria chronicity: why within-host models struggle to reproduce infection dynamics. *Journal of the Royal Society, Interface*. 2014; doi: <https://doi.org/10.1098/rsif.2014.1379>.
- 1029
- 1030
- 1031 **Choi DW**, Kim NK, Chae KC. A Two-Moment Approximation for the GI/G/c Queue with Finite Capacity. *INFORMS Journal on Computing*. 2005; 17(1):75–81. <https://doi.org/10.1287/ijoc.1030.0058>, doi: [10.1287/ijoc.1030.0058](https://doi.org/10.1287/ijoc.1030.0058).
- 1032
- 1033
- 1034 **Chu CS**, White NJ. Management of relapsing *Plasmodium vivax* malaria. *Expert Rev Anti Infect Ther*. 2016; doi: [10.1080/14787210.2016.1220304](https://doi.org/10.1080/14787210.2016.1220304).
- 1035
- 1036 **Claessens A**, Adams Y, Ghumra A, et al. A subset of group A-like *var* genes encodes the malaria parasite ligands for binding to human brain endothelial cells. *Proc Natl Acad Sci USA*. 2012; doi: [10.1073/pnas.1120461109](https://doi.org/10.1073/pnas.1120461109).
- 1037
- 1038 **Claessens A**, Hamilton WL, Kekre M, D OT, Faizullabhoj A, Rayner JC, Kwiatkowski D. Generation of Antigenic Diversity in *Plasmodium falciparum* by Structured Rearrangement of *Var* Genes During Mitosis. *PLoS Genet*. 2014; doi: <https://doi.org/10.1371/journal.pgen.1004812>.
- 1039
- 1040
- 1041 **Collins WE**, Jeffery GM. A retrospective examination of sporozoite- and trophozoite-induced infections with *Plasmodium falciparum* in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity. *Am J Trop Med Hyg*. 1999; doi: [10.4269/tropmed.1999.61-036](https://doi.org/10.4269/tropmed.1999.61-036).
- 1042
- 1043
- 1044
- 1045 **Daniels R**, Volkman SK, Milner DA, et al. A general SNP-based molecular barcode for *Plasmodium falciparum* identification and tracking. *Malar J*. 2008; doi: <https://doi.org/10.1186/1475-2875-7-223>.
- 1046
- 1047 **Daubersies P**, Sallenave-Sales S, Magne S, Trape JF, Contamin H, Fandeur T, Rogier C, Mercereau-Puijalon O, Druilhe P. Rapid turnover of *Plasmodium falciparum* populations in asymptomatic individuals living in a high transmission area. *The American journal of tropical medicine and hygiene*. 1996; doi: <https://doi.org/10.4269/ajtmh.1996.54.18>.
- 1048
- 1049
- 1050
- 1051 **Day KP**, Artzy-Randrup Y, Tiedje KE, Rougeron V, Chen DS, Rask TS, Rorick MM, Migot-Nabias F, Deloron P, Luty AJF, Pascual M. Evidence of strain structure in *Plasmodium falciparum var* gene repertoires in children from Gabon, West Africa. *Proceedings of the National Academy of Sciences*. 2017; doi: <https://doi.org/10.1073/pnas.1613018114>.
- 1052
- 1053
- 1054
- 1055 **Deitsch KW**, Lukehart SA, Stringer JR. Common strategies for antigenic variation by bacterial, fungal and protozoan pathogens. *Nature reviews*. 2009; doi: <https://doi.org/10.1038/nrmicro2145>.
- 1056
- 1057 **Dietz K**, Molineaux L, Thomas A. A malaria model tested in the African savannah. *Bull World Health Organ*. 1974; .
- 1058
- 1059 **Donovan MJ**, Messmore AS, Scraftord DA, Sacks DL, Kamhawi S, McDowell MA. Uninfected mosquito bites confer protection against infection with malaria parasites. *Infection and immunity*. 2007; doi: <https://doi.org/10.1128/IAI.01928-06>.
- 1060
- 1061
- 1062 **Doolan DL**, Dobaño C, Baird JK. Acquired immunity to malaria. *Clin Microbiol Rev*. 2009; doi: [10.1128/CMR.00025-08](https://doi.org/10.1128/CMR.00025-08).
- 1063
- 1064 **Doolan DL**, Martinez-Alier N. Immune response to pre-erythrocytic stages of malaria parasites. *Curr Mol Med*. 2006; doi: [10.2174/156652406776055249](https://doi.org/10.2174/156652406776055249).
- 1065

- 1066 **Earland D**, Buchwald AG, Sixpence A, Chimanya M, Damson M, Seydel KB, Mathanga DP, Taylor TE, Laufer
1067 MK. Impact of Multiplicity of *Plasmodium falciparum* Infection on Clinical Disease in Malawi. The American
1068 Journal of Tropical Medicine and Hygiene. 2019; doi: <https://doi.org/10.4269/ajtmh.19-0093>.
- 1069 **Efron B**, Tibshirani RJ. An Introduction to the Bootstrap (1st ed.); 1994. doi:
1070 <https://doi.org/10.1201/9780429246593>.
- 1071 **Farnert A**, Snounou G, Rooth I, Bjorkman A. Daily dynamics of *Plasmodium falciparum* subpopulations in asym-
1072 ptomatic children in a holoendemic area. The American journal of tropical medicine and hygiene. 1997; doi:
1073 <https://doi.org/10.4269/ajtmh.1997.56.538>.
- 1074 **Felger I**, Tavul L, Kabintik S, Marshall V, Genton B, Alpers M, Beck HP. *Plasmodium falciparum*: Exten-
1075 sive Polymorphism in Merozoite Surface Antigen 2 Alleles in an Area with Endemic Malaria in Papua New
1076 Guinea. Experimental Parasitology. 1994; 79(2):106–116. [https://www.sciencedirect.com/science/article/pii/](https://www.sciencedirect.com/science/article/pii/S0014489484710708)
1077 [S0014489484710708](https://doi.org/10.1006/expr.1994.1070), doi: <https://doi.org/10.1006/expr.1994.1070>.
- 1078 **Felger I**, Maire M, Bretscher MT, Falk N, Tiaden A, Sama W, Beck HP, Owusu-Agyei S, Smith
1079 TA. The Dynamics of Natural *Plasmodium falciparum* Infections. PLoS ONE. 2012; doi:
1080 <https://doi.org/10.1371/journal.pone.0045542>.
- 1081 **Frank M**, Kirkman L, Costantini D, Sanyal S, Lavazec C, Templeton TJ, Deitsch KW. Frequent recombination
1082 events generate diversity within the multi-copy variant antigen gene families of *Plasmodium falciparum*. In-
1083 ternational journal for parasitology. 2008; doi: <https://doi.org/10.1016/j.ijpara.2008.01.010>.
- 1084 **Freitas-Junior LH**, Bottius E, Pirrit LA, et al. Frequent ectopic recombination of virulence factor genes in telom-
1085 eric chromosome clusters of *P. falciparum*. Nature. 2000; doi: 10.1038/35039531.
- 1086 **Färnert A**, Lebbad M, Faraja L, Rooth I. Extensive dynamics of *Plasmodium falciparum* densities, stages and
1087 genotyping profiles. Malar J. 2008; doi: 10.1186/1475-2875-7-241.
- 1088 **Gardner MJ**, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman
1089 S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom
1090 SJ, et al. Genome sequence of the human malaria parasite *Plasmodium falciparum*. Nature. 2002; doi:
1091 <https://doi.org/10.1038/nature01097>.
- 1092 **Gibson MA**, Bruck J. Efficient Exact Stochastic Simulation of Chemical Systems with Many Species and Many
1093 Channels. The Journal of Physical Chemistry A. 2000; doi: 10.1021/jp993732q.
- 1094 **Gillespie DT**. A General Method for Numerically Simulating the Stochastic Time Evolution of Coupled Chemical
1095 Reactions. Journal of Computational Physics. 1976; doi: [http://dx.doi.org/10.1016/0021-9991\(76\)90041-3](http://dx.doi.org/10.1016/0021-9991(76)90041-3).
- 1096 **Gogue C**, Wagman J, Tynuv K, et al. An observational analysis of the impact of indoor residual spraying
1097 in Northern, Upper East, and Upper West Regions of Ghana: 2014 through 2017. Malar J. 2020; doi:
1098 <https://doi.org/10.1186/s12936-020-03318-1>.
- 1099 **Guttery DS**, Holder AA, Tewari R. Sexual development in *Plasmodium*: lessons from functional analyses. PLoS
1100 pathogens. 2012; doi: <https://doi.org/10.1371/journal.ppat.1002404>.
- 1101 **He Q**, Pilosof S, Tiedje KE, Ruybal-Pesántez S, Artzy-Randrup Y, Baskerville EB, Day KP, Pascual M. Networks
1102 of genetic similarity reveal non-neutral processes shape strain structure in *Plasmodium falciparum*. Nature
1103 Communications. 2018; doi: <https://doi.org/10.1038/s41467-018-04219-3>.
- 1104 **Hergott DEB**, Owalla TJ, Staubus WJ, et al. Assessing the daily natural history of asymptomatic *Plasmodium*
1105 infections in adults and older children in Katakwi, Uganda: a longitudinal cohort study. The Lancet Microbe.
1106 2024; doi: 10.1016/S2666-5247(23)00262-8.
- 1107 **Hofmann NE**, Karl S, Wampfler R, Kiniboro B, Teliki A, Iga J, Waltmann A, Betuela I, Felger I, Robinson LJ, Mueller
1108 I. The complex relationship of exposure to new *Plasmodium* infections and incidence of clinical malaria in
1109 Papua New Guinea. eLife. 2017; doi: <https://doi.org/10.7554/eLife.23708>.
- 1110 **John CC**, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-
1111 erythrocytic *Plasmodium falciparum* antigens and protection from infection. Am J Trop Med Hyg. 2005; doi:
1112 <https://doi.org/10.4269/ajtmh.2005.73.222>.
- 1113 **Johnston SP**, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, Silva A. PCR as a confirmatory technique
1114 for laboratory diagnosis of malaria. J Clin Microbiol. 2006; doi: 10.1128/JCM.44.3.1087-1089.2006.

- 1115 **Kaestli M**, Cockburn IA, Cortés A, Baea K, Rowe JA, Beck HP. Virulence of malaria is associated with differential
1116 expression of *Plasmodium falciparum* var gene subgroups in a case-control study. *J Infect Dis*. 2006; doi:
1117 10.1086/503776.
- 1118 **Konaté L**, Zwetyenga J, Rogier C, Bischoff E, Fontenille D, Tall A, Spiegel A, Trape JF, Mercereau-Puijalon O. 5.
1119 Variation of *Plasmodium falciparum* msp1 block 2 and msp2 allele prevalence and of infection complexity in
1120 two neighbouring Senegalese villages with different transmission conditions. *Transactions of The Royal Society*
1121 *of Tropical Medicine and Hygiene*. 1999 02; 93(Supplement₁) : 21 – 28., 10.1016/S0035-9203(99)90323-1.
- 1122 **Kraemer SM**, Kyes SA, Aggarwal G, Springer AL, Nelson SO, Christodoulou Z, Smith LM, Wang W,
1123 Levin E, Newbold CI, Myler PJ, Smith JD. Patterns of gene recombination shape var gene repertoires
1124 in *Plasmodium falciparum*: comparisons of geographically diverse isolates. *BMC Genomics*. 2007;
1125 <https://doi.org/10.1186/1471-2164-8-45>.
- 1126 **Labbé F**, He Q, Zhan Q, Tiedje KE, Argyropoulos DC, Tan MH, Ghansah A, Day KP, Pascual M. Neutral
1127 vs. non-neutral genetic footprints of *Plasmodium falciparum* multiclonal infections. *PLoS Computa-*
1128 *tional Biology*. 2023; <https://doi.org/10.1371/journal.pcbi.1010816>.
- 1129 **Laishram DD**, Sutton PL, Nanda N, Sharma VL, Sobti RC, Carlton JM, Joshi H. The complexities
1130 of malaria disease manifestations with a focus on asymptomatic malaria. *Malaria journal*. 2012;
1131 <https://doi.org/10.1186/1475-2875-11-29>.
- 1132 **Langhorne J**, Ndungu FM, Sponaas AM, Marsh K. Immunity to malaria: more questions than an-
1133 swers. *Nat Immunol*. 2008; <https://doi.org/10.1038/ni.f.205>.
- 1134 **Larremore DB**, Clauset A, Buckee CO. A network approach to analyzing highly recombinant malaria
1135 parasite genes. *PLoS Comput Biol*. 2013; [10.1371/journal.pcbi.1003268](https://doi.org/10.1371/journal.pcbi.1003268).
- 1136 **Lavstsen T**, Salanti A, Jensen ATR, Arnot DE, Theander TG. Sub-grouping of *Plasmodium falciparum*
1137 3D7 var genes based on sequence analysis of coding and non-coding regions. *Malaria journal*.
1138 2003; <https://doi.org/10.1186/1475-2875-2-27>.
- 1139 **Lee SA**, Yeka A, Nsoya SL, Dokomajilar C, Rosenthal PJ, Talisuna A, Dorsey G. Complexity of Plas-
1140 modium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. *The Journal of*
1141 *infectious diseases*. 2006; <https://doi.org/10.1086/501473>.
- 1142 **Lindblade KA**, Steinhardt L, Samuels A, Kachur SP, Slutsker L. The silent threat: asymptomatic
1143 parasitemia and malaria transmission. *Expert Rev Anti Infect Ther*. 2013; [10.1586/eri.13.45](https://doi.org/10.1586/eri.13.45).
- 1144 **Little JDC**, Graves SC. Little's Law. In: Chhajed D, Lowe TJ, editors. *Building Intuition International*
1145 *Series in Operations Research & Management Science*, Springer; 2008.p. 81–100. [https://ideas.](https://ideas.repec.org/h/spr/isochp/978-0-387-73699-0_5.html)
1146 [repec.org/h/spr/isochp/978-0-387-73699-0_5.html](https://ideas.repec.org/h/spr/isochp/978-0-387-73699-0_5.html), 10.1007/978-0-387-73699-0.
- 1147 **Lloyd-Smith JO**, Schreiber SJ, Kopp PE, Getz WM. Superspreading and the effect of individual vari-
1148 ation on disease emergence. *Nature*. 2005; 10.1038/nature04153.
- 1149 **Macdonald G**. The analysis of malaria parasite rates in infants. *Tropical diseases bulletin*. 1950; .
- 1150 **Maire N**, Smith T, Ross A, Owusu-Agyei S, Dietz K, Molineaux L. A model for natural immunity to
1151 asexual blood stages of *Plasmodium falciparum* malaria in endemic areas. *Am J Trop Med Hyg*.
1152 2006; [10.4269/ajtmh.2006.75.19](https://doi.org/10.4269/ajtmh.2006.75.19).
- 1153 **Molineaux L**, Träuble M, Collins WE, Jeffery GM, Dietz K. Malaria therapy reinoculation data suggest
1154 individual variation of an innate immune response and independent acquisition of antiparasitic
1155 and antitoxic immunities. *Transactions of the Royal Society of Tropical Medicine and Hygiene*.
1156 2002; [https://doi.org/10.1016/s0035-9203\(02\)90308-1](https://doi.org/10.1016/s0035-9203(02)90308-1).
- 1157 **Msuya FH**, Curtis CF. Trial of pyrethroid impregnated bednets in an area of Tanzania holoendemic
1158 for malaria. Part 4. Effects on incidence of malaria infection. *Acta Trop*. 1991; 10.1016/0001-
1159 706x(91)90035-i.

- 1160 **Mueller I**, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B, Zimmerman PA, Speed
1161 TP, Siba P, Felger I. Force of infection is key to understanding the epidemiology of *Plasmodium falciparum*
1162 malaria in Papua New Guinean children. Proceedings of the National Academy of Sciences
1163 of the United States of America. 2012; <https://doi.org/10.1073/pnas.1200841109>.
- 1164 **Muench H**. Catalytic models in epidemiology. Harvard University Press. 1959; .
- 1165 **Mugenyi L**, Abrams S, Hens N. Estimating age-time-dependent malaria force of infection account-
1166 ing for unobserved heterogeneity. Epidemiology and Infection. 2017; 145(12):2545–2562. [10.1017/S0950268817000000](https://doi.org/10.1017/S0950268817000000)
- 1167 **Nkhoma SC**, Trevino SG, Gorena KM, Nair S, Khoswe S, Jett C, Garcia R, Daniel B, Dia A, Terlouw
1168 DJ, Ward SA, Anderson TJC, Cheeseman IH. Co-transmission of Related Malaria Parasite Lineages
1169 Shapes Within-Host Parasite Diversity. Cell host & microbe. 2020; <https://doi.org/10.1016/j.chom.2019.12.001>
- 1170 **Okell LC**, Bousema T, Griffin JT, Ouédraogo AL, Ghani AC, Drakeley CJ. Factors determining the
1171 occurrence of submicroscopic malaria infections and their relevance for control. Nature commu-
1172 nications. 2012; <https://doi.org/10.1038/ncomms2241>.
- 1173 **Peyerl-Hoffmann G**, Jelinek T, Kilian A, Kabagambe G, Metzger WG, von Sonnenburg F. Genetic
1174 diversity of *Plasmodium falciparum* and its relationship to parasite density in an area with different
1175 malaria endemicities in West Uganda. Trop Med Int Health. 2001; [10.1046/j.1365-3156.2001.00761.x](https://doi.org/10.1046/j.1365-3156.2001.00761.x).
- 1176 **Pilosof S**, He Q, Tiedje KE, Ruybal-Pesántez S, Day KP, Pascual M. Competition for hosts modulates
1177 vast antigenic diversity to generate persistent strain structure in *Plasmodium falciparum*. PLoS
1178 Biology. 2019; <https://doi.org/10.1371/journal.pbio.3000336>.
- 1179 **Piper KP**, Roberts DJ, Day KP. Plasmodium falciparum: analysis of the antibody specificity to the sur-
1180 face of the trophozoite-infected erythrocyte. Experimental parasitology. 1999; <https://doi.org/10.1006/expr.1999.3700>
- 1181 **Portugal S**, Drakesmith H, Mota MM. Superinfection in malaria: Plasmodium shows its iron will.
1182 EMBO reports. 2011; [10.1038/embor.2011.213](https://doi.org/10.1038/embor.2011.213).
- 1183 **Potthoff RF**, Whittinghill M. Testing for homogeneity. II. The Poisson distribution. Biometrika.
1184 1966; <https://doi.org/10.1093/biomet/53.1-2.183>.
- 1185 **Pull JH**, Grab B. A simple epidemiological model for evaluating the malaria inoculation rate and
1186 the risk of infection in infants. Bulletin of the World Health Organization. 1974; .
- 1187 **Rask TS**, Hansen DA, Theander TG, Pedersen AG, Lavstsen T. *Plasmodium falciparum* erythrocyte
1188 membrane protein 1 diversity in seven genomes—divide and conquer. PLoS computational biology.
1189 2010; <https://doi.org/10.1371/journal.pcbi.1000933>.
- 1190 **de Roos AM**, He Q, M P. An immune memory-structured SIS epidemiological model for hyperdi-
1191 verse pathogens. Proc Natl Acad Sci USA. 2023; [10.1073/pnas.2218499120](https://doi.org/10.1073/pnas.2218499120).
- 1192 **Rottmann M**, Lavstsen T, Mugasa JP, et al. Differential expression of *var* gene groups is associated
1193 with morbidity caused by *Plasmodium falciparum* infection in Tanzanian children. Infect Immun.
1194 2006; [10.1128/IAI.02073-05](https://doi.org/10.1128/IAI.02073-05).
- 1195 **Ruybal-Pesántez S**, Tiedje KE, Pilosof S, Tonkin-Hill G, He Q, Rask TS, Amenga-Etego L, Oduro AR,
1196 Koram KA, Pascual M, Day KP. Age-specific patterns of DBL α var diversity can explain why residents
1197 of high malaria transmission areas remain susceptible to *Plasmodium falciparum* blood stage infec-
1198 tion throughout life. International Journal for Parasitology. 2022; <https://doi.org/10.1016/j.ijpara.2021.12.001>
- 1199 **Ruybal-Pesántez S**, Tiedje KE, Tonkin-Hill G, Rask TS, Kanya MR, Greenhouse B, Dorsey G, Duffy
1200 MF, Day KP. Population genomics of virulence genes of Plasmodium falciparum in clinical isolates
1201 from Uganda. Sci Rep. 2017; <https://doi.org/10.1038/s41598-017-11814-9>.
- 1202 **Shaukat AM**, Breman JG, McKenzie FE. Using the entomological inoculation rate to assess the
1203 impact of vector control on malaria parasite transmission and elimination. Malaria journal. 2010;
1204 <https://doi.org/10.1186/1475-2875-9-122>.

- 1205 **Simpson JA**, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of untreated *Plasmodium falciparum* malaria within the adult human host during the expansion phase of the infection. Parasitology. 2002; <https://doi.org/10.1017/s0031182001001202>.
- 1206
- 1207
- 1208 **Smith DL**, Drakeley CJ, Chiyaka C, Hay SI. A quantitative analysis of transmission efficiency versus intensity for malaria. Nature Communication. 2010; <https://doi.org/10.1038/ncomms1107>.
- 1209
- 1210 **Smith JD**, Chitnis CE, Craig AG, et al. Switches in expression of *Plasmodium falciparum var* genes correlate with changes in antigenic and cytoadherent phenotypes of infected erythrocytes. Cell. 1995; 10.1016/0092-8674(95)90056-x.
- 1211
- 1212
- 1213 **Smith T**, Vounatsou P. Estimation of infection and recovery rates for highly polymorphic parasites when detectability is imperfect, using hidden Markov models. Statistics in medicine. 2003; <https://doi.org/10.1002/sim.1274>.
- 1214
- 1215
- 1216 **Sondo P**, Derra K, Rouamba T, Diallo SN, Taconet P, Kazienga A, Ilboudo H, Tahita MC, Valéa I, Sorgho H, Lefèvre T, Tinto H. Determinants of *Plasmodium falciparum* multiplicity of infection and genetic diversity in Burkina Faso. Parasites Vectors. 2020; <https://doi.org/10.1186/s13071-020-04302-z>.
- 1217
- 1218
- 1219
- 1220 **Su XZ**, Heatwole VM, Wertheimer SP, et al. The large diverse gene family *var* encodes proteins involved in cytoadherence and antigenic variation of *Plasmodium falciparum*-infected erythrocytes. Cell. 1995; 10.1016/0092-8674(95)90055-1.
- 1221
- 1222
- 1223 **Tan MH**, Shim H, Chan Y, Day KP. Unravelling *var* complexity: Relationship between DBL α types and *var* genes in *Plasmodium falciparum*. Front Parasitol. 2023; [10.3389/fpara.2022.1006341](https://doi.org/10.3389/fpara.2022.1006341).
- 1224
- 1225 **Tiedje KE**, Oduro AR, Agongo G, Anyorigiya T, Azongo D, Awine T, Ghansah A, Pascual M, Koram KA, Day KP. Seasonal Variation in the Epidemiology of Asymptomatic *Plasmodium falciparum* Infections across Two Catchment Areas in Bongo District, Ghana. Am J Trop Med Hyg. 2017; [10.4269/ajtmh.16-0959](https://doi.org/10.4269/ajtmh.16-0959).
- 1226
- 1227
- 1228
- 1229 **Tiedje KE**, Oduro AR, Bangre O, Amenga-Etego L, Dadzie SK, Appawu MA, Frempong K, Asoala V, Ruybal-Pésantez S, Narh CA, Deed SL, Argyropoulos DC, Ghansah A, Agyei SA, Segbaya S, Desewu K, Williams I, Simpson JA, Malm K, Pascual M, et al. Indoor residual spraying with a non-pyrethroid insecticide reduces the reservoir of *Plasmodium falciparum* in a high-transmission area in northern Ghana. PLOS Global Public Health. 2022; <https://doi.org/10.1371/journal.pgph.0000285>.
- 1230
- 1231
- 1232
- 1233
- 1234 **Tiedje KE**, Zhan Q, Ruybal-Pésantez S, Tonkin-Hill G, He Q, Tan MH, Argyropoulos DC, Deed SL, Ghansah A, Bangre O, Oduro AR, Koram KA, Pascual M, Day KP. Measuring changes in *Plasmodium falciparum var* census population size and structure in response to sequential malaria control interventions. eLife. 2023; <https://doi.org/10.7554/eLife.91411.1>.
- 1235
- 1236
- 1237
- 1238 **Touray AO**, Mobegi VA, Wamunyokoli F, Herren JK. Diversity and Multiplicity of *P. falciparum* infections among asymptomatic school children in Mbita, Western Kenya. Sci Rep. 2020; [doi:10.1038/s41598-020-62819-w](https://doi.org/10.1038/s41598-020-62819-w).
- 1239
- 1240
- 1241 **Tusting LS**, Bousema T, Smith DL, Drakeley C. Measuring changes in *Plasmodium falciparum* transmission: precision, accuracy and costs of metrics. Advances in parasitology. 2014; <https://doi.org/10.1016/B0-12-800099-1.00003-X>.
- 1242
- 1243
- 1244 **Volkman S**, Neafsey D, Schaffner S, et al. Harnessing genomics and genome biology to understand malaria biology. Nat Rev Genet. 2012; 10.1038/nrg3187.
- 1245
- 1246 **White MT**, Griffin JT, Churcher TS, Ferguson NM, Basáñez MG, Ghani AC. Modelling the impact of vector control interventions on *Anopheles gambiae* population dynamics. Parasites Vectors. 2011; <https://doi.org/10.1186/1756-3305-4-153>.
- 1247
- 1248

- 1249 **Wong W**, Griggs AD, Daniels RF, Schaffner SF, Ndiaye D, Bei AK, Deme AB, MacInnis B, Volkman SK,
1250 Hartl DL, Neafsey DE, Wirth DF. Genetic relatedness analysis reveals the cotransmission of geneti-
1251 cally related *Plasmodium falciparum* parasites in Thiès, Senegal. *Genome Med.* 2017; [https://doi.org/10.1186/](https://doi.org/10.1186/s13059-017-0398-0)
1252 [s13059-017-0398-0](https://doi.org/10.1186/s13059-017-0398-0).
- 1253 **Wong W**, Volkman S, Daniels R, Schaffner S, Sy M, Ndiaye YD, Badiane AS, Deme AB, Diallo MA,
1254 Gomis J, Sy N, Ndiaye D, Wirth DF, Hartl DL. RH: a genetic metric for measuring intrahost *Plasmod-*
1255 *ium falciparum* relatedness and distinguishing cotransmission from superinfection. *PNAS Nexus.*
1256 2022; <https://doi.org/10.1093/pnasnexus/pgac187>.
- 1257 **World Health Organization**. Indoor Residual Spraying: An Operational Manual for Indoor Resid-
1258 ual Spraying (IRS) for Malaria Transmission Control and Elimination. World Health Organization;
1259 2015.
- 1260 **World Health Organization**. World malaria report 2023. World Health Organization; 2023.
- 1261 **Zhan Q**, He Q, Tiedje K, Day KP, Pascual M. Hyper-diverse antigenic variation and resilience to
1262 transmission-reducing intervention in falciparum malaria. *medRxiv.* 2024; <https://doi.org/10.1101/2024.02.12.24302148>.
- 1263 **Zhang X**, Deitsch KW. The mystery of persistent, asymptomatic *Plasmodium falciparum* infections.
1264 *Curr Opin Microbiol.* 2022; [10.1016/j.mib.2022.102231](https://doi.org/10.1016/j.mib.2022.102231).
- 1265 **Zhong D**, Koepfli C, Cui L, Yan G. Molecular approaches to determine the multiplicity of *Plasmodium*
1266 infections. *Malaria Journal.* 2018; <https://doi.org/10.1186/s12936-018-2322-5>.